ALPHASUITEATLASTM
BRCA2 · P51587Homo sapiens
PROTEIN OVERVIEW

BRCA2Breast cancer type 2 susceptibility protein

P51587Homo sapiensReviewed · UniProt

Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR).

Sequence3418 aa
Source mass384.23 kDa
Recorded PDB entries14
Isoforms listed1

UniProt locations Chromosome · Chromosome, telomere · Nucleus · Cytoplasm, cytoskeleton, microtubule organizing center, centrosome

01

Function

Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR) [11, 47, 12, 13, 16, 18, 23, 22, 26, 27, 32, 30, 29, 94, 40, 46, 45]. Facilitates the repair of double-strand breaks (DSBs) by binding and mediating the loading of the RAD51 protein onto single-stranded DNA (ssDNA), thereby promoting the activity of RAD51, which catalyzes DNA strand exchange [11, 47, 18, 23, 22, 26, 27, 32, 30, 29, 40, 46]. BRCA2 nucleates and stabilizes RAD51 on ssDNA directly and delivers RAD51 to ssDNA-double-stranded DNA (dsDNA) junctions by sliding along dsDNA backbone [47, 27, 46].

RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis [29]. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity [38]. Required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability [39].

Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination [39]. Also promotes RAD51 loading to telomeric regions, facilitating telomere replication and capping [31]. Also required for homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 recombinases to meiotic DSB sites, enabling proper chromosome pairing and crossing over [42].

Also promotes homologous recombination by inactivating the FIGNL1-FIRRM complex to protect RAD51 filament from premature disassembly [45]. Together with NPM1, may also regulate centrosome duplication [33]

Experimental evidence 22 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11239456"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12442171"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15115758"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15199141"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15671039"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15937124"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515903"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515904"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18317453"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19303847"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20729832"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20729858"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20729859"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21076401"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21084279"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21719596"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24485656"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24896180"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "26976601"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27941124"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "37499663"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "37515771"
        }
      ],
      "value": "Tumor suppressor protein that maintains genome stability primarily by repairing damaged DNA through homologous recombination (HR) (PubMed:11239456, PubMed:12442171, PubMed:15115758, PubMed:15199141, PubMed:15671039, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:21719596, PubMed:27941124, PubMed:37499663, PubMed:37515771). Facilitates the repair of double-strand breaks (DSBs) by binding and mediating the loading of the RAD51 protein onto single-stranded DNA (ssDNA), thereby promoting the activity of RAD51, which catalyzes DNA strand exchange (PubMed:11239456, PubMed:12442171, PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729858, PubMed:20729859, PubMed:27941124, PubMed:37499663). BRCA2 nucleates and stabilizes RAD51 on ssDNA directly and delivers RAD51 to ssDNA-double-stranded DNA (dsDNA) junctions by sliding along dsDNA backbone (PubMed:12442171, PubMed:19303847, PubMed:37499663). RAD51 targeting to ssDNA promotes removal of replication protein-A (RPA) from ssDNA and stabilization of RAD51-ssDNA filaments by blocking ATP hydrolysis (PubMed:20729859). May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity (PubMed:24485656). Required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability (PubMed:24896180). Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180). Also promotes RAD51 loading to telomeric regions, facilitating telomere replication and capping (PubMed:21076401). Also required for homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 recombinases to meiotic DSB sites, enabling proper chromosome pairing and crossing over (PubMed:26976601). Also promotes homologous recombination by inactivating the FIGNL1-FIRRM complex to protect RAD51 filament from premature disassembly (PubMed:37515771). Together with NPM1, may also regulate centrosome duplication (PubMed:21084279)"
    }
  ],
  "commentType": "FUNCTION"
}

GO functions & biological processes

histone acetyltransferase activityNOT|enablesUniProtKB:P51587
GO
GO:0004402 · evidence & context
protease bindingenablesUniProtKB:P51587
GO
GO:0002020 · evidence & context
  • ECO:0000353 PMID:15314155 ↗ IPI · UniProt · 20100604
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51784"}]}]
double-stranded DNA bindingenablesUniProtKB:P51587
GO
GO:0003690 · evidence & context
single-stranded DNA bindingenablesUniProtKB:P51587
GO
GO:0003697 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250320
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2219"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
  • ECO:0000314 PMID:20729832 ↗ IDA · UniProt · 20101006
    qualifier: enables
  • ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302
    qualifier: enables
protein bindingenablesUniProtKB:P51587
GO
GO:0005515 · evidence & context
  • ECO:0000353 PMID:10373512 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
  • ECO:0000353 PMID:10373512 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
  • ECO:0000353 PMID:10551859 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:11597317 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:12242698 ↗ IPI · UniProt · 20090624
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P38398"}]}]
  • ECO:0000353 PMID:12242698 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9GKK8"}]}]
  • ECO:0000353 PMID:12442171 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:15115758 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BXW9"}]}]
  • ECO:0000353 PMID:15800615 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:15930293 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y5V3"}]}]
  • ECO:0000353 PMID:15967112 ↗ IPI · UniProt · 20070813
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N1V2"}]}]
  • ECO:0000353 PMID:16099937 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P02768"}]}]
  • ECO:0000353 PMID:16205630 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
  • ECO:0000353 PMID:16275750 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8N137"}]}]
  • ECO:0000353 PMID:17515903 ↗ IPI · UniProt · 20070808
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:17515903 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609-1"}]}]
  • ECO:0000353 PMID:17515904 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609-1"}]}]
  • ECO:0000353 PMID:17541404 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:17541404 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565"}]}]
  • ECO:0000353 PMID:18212739 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BXW9"}]}]
  • ECO:0000353 PMID:18212739 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9BXW9-2"}]}]
  • ECO:0000353 PMID:18264088 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:19303847 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:19423707 ↗ IPI · UniProt · 20101007
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
  • ECO:0000353 PMID:19628690 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:20421506 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P04637"}]}]
  • ECO:0000353 PMID:20729832 ↗ IPI · UniProt · 20101006
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:20729832 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:20729832 ↗ IPI · UniProt · 20101006
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565"}]}]
  • ECO:0000353 PMID:20729832 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565"}]}]
  • ECO:0000353 PMID:20729859 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:21399666 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:21399666 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9P0W2"}]}]
  • ECO:0000353 PMID:21601571 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:21719596 ↗ IPI · UniProt · 20160118
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
  • ECO:0000353 PMID:22116401 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
  • ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NTI5"}]}]
  • ECO:0000353 PMID:24013206 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P60896"}]}]
  • ECO:0000353 PMID:24981860 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:25282148 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:25585578 ↗ IPI · UniProt · 20151008
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000353 PMID:26833090 ↗ IPI · UniProt · 20210120
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28715"}, {"db": "UniProtKB", "id": "P60896"}, {"db": "UniProtKB", "id": "Q06609"}, {"db": "UniProtKB", "id": "Q86YC2"}]}]
  • ECO:0000353 PMID:31242413 ↗ IPI · UniProt · 20200907
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O75031"}]}]
  • ECO:0000353 PMID:39009827 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9GZQ8"}]}]
  • ECO:0000353 PMID:9560268 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609"}]}]
  • ECO:0000314 PMID:9774970 ↗ IDA · MGI · 20160830
    qualifier: enables
  • ECO:0000353 PMID:9774970 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P38398"}]}]
All recorded function and process assertions (32)
protein bindingenablesUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:0005515 · evidence & context
  • ECO:0000353 PMID:17420451 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:19369211 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:19609323 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:22193777 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:22293751 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:24141787 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:24485656 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:24485656 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y253"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:28319063 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:30410870 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:33961781 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
  • ECO:0000353 PMID:34591612 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86YC2"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0035861", "relation": "occurs_in"}]}]
protein-macromolecule adaptor activityenablesUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:0030674 · evidence & context
  • ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
  • ECO:0000314 PMID:15937124 ↗ IDA · UniProt · 20260224
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
  • ECO:0000314 PMID:17515903 ↗ IDA · UniProt · 20260224
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
  • ECO:0000314 PMID:17515904 ↗ IDA · UniProt · 20260224
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
  • ECO:0000314 PMID:19303847 ↗ IDA · UniProt · 20260224
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
  • ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
protein-macromolecule adaptor activityenablesUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:0030674 · evidence & context
  • ECO:0000314 PMID:39333100 ↗ IDA · UniProt · 20260310
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14565", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "1990918", "relation": "part_of"}]}]
identical protein bindingenablesUniProtKB:P51587
GO
GO:0042802 · evidence & context
  • ECO:0000353 PMID:21601571 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
  • ECO:0000353 PMID:25282148 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
gamma-tubulin bindingenablesUniProtKB:P51587
GO
GO:0043015 · evidence & context
  • ECO:0000353 PMID:17286961 ↗ IPI · UniProt · 20070807
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P23258"}]}]
molecular function inhibitor activityenablesUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:0140678 · evidence & context
  • ECO:0000314 PMID:37515771 ↗ IDA · UniProt · 20260304
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q6PIW4", "relation": "has_input"}, {"db": "GO", "id": "0000730", "relation": "part_of"}, {"db": "GO", "id": "0000724", "relation": "part_of"}]}]
telomere maintenance via recombinationinvolved inUniProtKB:P51587
GO
GO:0000722 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
double-strand break repair via homologous recombinationinvolved inUniProtKB:P51587
GO
GO:0000724 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR015187"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR015525"}]}]
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260528
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "AGI_LocusCode", "id": "AT4G00020"}]}, {"connectedXrefs": [{"db": "AGI_LocusCode", "id": "AT5G01630"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:109337"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
  • ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224
    qualifier: involved_in
  • ECO:0000314 PMID:15937124 ↗ IDA · UniProt · 20260224
    qualifier: involved_in
  • ECO:0000314 PMID:17515903 ↗ IDA · UniProt · 20260224
    qualifier: involved_in
  • ECO:0000314 PMID:17515904 ↗ IDA · UniProt · 20260224
    qualifier: involved_in
  • ECO:0000314 PMID:19303847 ↗ IDA · UniProt · 20260224
    qualifier: involved_in
  • ECO:0000314 PMID:20729832 ↗ IDA · UniProt · 20101006
    qualifier: involved_in
  • ECO:0000315 PMID:21719596 ↗ IMP · UniProt · 20160118
    qualifier: involved_in
  • ECO:0000314 PMID:27941124 ↗ IDA · UniProt · 20260226
    qualifier: involved_in
  • ECO:0000314 PMID:28398198 ↗ IDA · ComplexPortal · 20251229
    qualifier: involved_in
  • ECO:0000314 PMID:37499663 ↗ IDA · UniProt · 20260302
    qualifier: involved_in
  • ECO:0000314 PMID:37515771 ↗ IDA · UniProt · 20260310
    qualifier: involved_in
DNA recombinase assemblyinvolved inUniProtKB:P51587
GO
GO:0000730 · evidence & context
DNA recombinase assemblyinvolved inUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:0000730 · evidence & context
  • ECO:0000314 PMID:39333100 ↗ IDA · UniProt · 20260310
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1990918", "relation": "part_of"}]}]
DNA repairinvolved inUniProtKB:P51587
GO
GO:0006281 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR015525"}]}]
nucleotide-excision repairinvolved inUniProtKB:P51587
GO
GO:0006289 · evidence & context
double-strand break repairinvolved inUniProtKB:P51587
GO
GO:0006302 · evidence & context
DNA recombinationinvolved inUniProtKB:P51587
GO
GO:0006310 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028026"}]}]
regulation of DNA-templated transcriptioninvolved inUniProtKB:P51587
GO
GO:0006355 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20220922
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "AGI_LocusCode", "id": "AT4G00020"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}]
DNA damage responseinvolved inUniProtKB:P51587
GO
GO:0006974 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
  • ECO:0000314 PMID:12442171 ↗ IDA · UniProt · 20260224
    qualifier: involved_in
meiosis Iinvolved inUniProtKB:P51587
GO
GO:0007127 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028964"}]}]
male meiosis Iinvolved inUniProtKB:P51587
GO
GO:0007141 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
negative regulation of mammary gland epithelial cell proliferationinvolved inUniProtKB:P51587
GO
GO:0033600 · evidence & context
positive regulation of DNA-templated transcriptioninvolved inUniProtKB:P51587
GO
GO:0045893 · evidence & context
centrosome duplicationinvolved inUniProtKB:P51587
GO
GO:0051298 · evidence & context
establishment of protein localization to telomereinvolved inUniProtKB:P51587
GO
GO:0070200 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
establishment of protein localization to telomereinvolved inUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:0070200 · evidence & context
  • ECO:0000314 PMID:21076401 ↗ IDA · BHF-UCL · 20151222
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06609", "relation": "has_input"}]}]
cellular response to ionizing radiationinvolved inUniProtKB:P51587
GO
GO:0071479 · evidence & context
mitotic recombination-dependent replication fork processinginvolved inUniProtKB:P51587 · Context-qualified assertion; see evidence
GO
GO:1990426 · evidence & context
  • ECO:0000315 PMID:21076401 ↗ IMP · BHF-UCL · 20151222
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0000781", "relation": "occurs_in"}]}]
double-strand break repair involved in meiotic recombinationinvolved inUniProtKB:P51587
GO
GO:1990918 · evidence & context
regulation of DNA damage checkpointinvolved inUniProtKB:P51587
GO
GO:2000001 · evidence & context
02

Names & Taxonomy

Recommended name
Breast cancer type 2 susceptibility protein
Gene
BRCA2
Accession / entry
P51587 · BRCA2_HUMAN
Species
Homo sapiens · NCBI 9606
Recorded aliases
FACD · FANCD1 · Fanconi anemia group D1 protein
Full taxonomy & recorded names

Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo

{
  "names": {
    "recommendedName": {
      "fullName": {
        "evidences": [
          {
            "evidenceCode": "ECO:0000303",
            "source": "PubMed",
            "id": "8524414"
          }
        ],
        "value": "Breast cancer type 2 susceptibility protein"
      }
    },
    "alternativeNames": [
      {
        "fullName": {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15199141"
            }
          ],
          "value": "Fanconi anemia group D1 protein"
        }
      }
    ]
  },
  "genes": [
    {
      "geneName": {
        "evidences": [
          {
            "evidenceCode": "ECO:0000303",
            "source": "PubMed",
            "id": "8524414"
          },
          {
            "evidenceCode": "ECO:0000312",
            "source": "HGNC",
            "id": "HGNC:1101"
          }
        ],
        "value": "BRCA2"
      },
      "synonyms": [
        {
          "value": "FACD"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15199141"
            }
          ],
          "value": "FANCD1"
        }
      ]
    }
  ]
}
03

Subcellular Location

UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.

ChromosomeReported location

Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress

UniProt
Experimental evidence 3 publications
Evidence & references
Chromosome, telomereReported location

Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress

UniProt
Experimental evidence 1 publication
Evidence & references
NucleusReported location

Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress

UniProt
Experimental evidenceCurator inference 3 publications
Evidence & references
Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeReported location

Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress

UniProt
Experimental evidence 1 publication
Evidence & references
nucleusis active in
GO
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250902
    qualifier: is_active_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:109337"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN000139030"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P51587"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q4GZF5"}]}]
site of double-strand breakis active in
GO
1 publication
Evidence & references
chromosome, telomeric regionlocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0276"}]}]
chromosome, telomeric regionlocated in

UniProtKB:P51587 · [{"connectedXrefs": [{"db": "GO", "id": "0000084", "relation": "existence_overlaps"}]}]

GO
1 publication
Evidence & references
  • ECO:0000314 PMID:21076401 ↗ IDA · BHF-UCL · 20151222
    qualifier: located_in
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0000084", "relation": "existence_overlaps"}]}]
All recorded location assertions (20)
lateral elementlocated in
GO
1 publication
Evidence & references
nucleuslocated in
GO
Experimental evidence 7 publications
Evidence & references
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
  • ECO:0000314 PMID:14636569 ↗ IDA · ComplexPortal · 20251229
    qualifier: located_in
  • ECO:0000314 PMID:17286961 ↗ IDA · UniProt · 20070807
    qualifier: located_in
  • ECO:0005547 PMID:19369211 ↗ NAS · ComplexPortal · 20251229
    qualifier: located_in
  • ECO:0000269 PMID:24013206 ↗ EXP · UniProt · 20250406
    qualifier: located_in
  • ECO:0000314 PMID:26833090 ↗ IDA · UniProt · 20210120
    qualifier: located_in
  • ECO:0000314 PMID:9560268 ↗ IDA · UniProt · 20070807
    qualifier: located_in
  • ECO:0000314 PMID:9774970 ↗ IDA · UniProt · 20070807
    qualifier: located_in
nucleoplasmlocated in
GO
Evidence & references
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5685242 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5685341 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5685838 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5686410 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5686440 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5686469 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5686483 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5693539 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5693561 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5693584 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5693589 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5693593 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5693620 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9701199 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9704330 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9704408 TAS · Reactome · 20150326
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9709273 TAS · Reactome · 20130213
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9709571 TAS · Reactome · 20220131
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9709601 TAS · Reactome · 20201216
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9853389 TAS · Reactome · 20150326
    qualifier: located_in
chromosomelocated in
GO
Evidence & references
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0468"}]}]
cytoplasmlocated in
GO
Evidence & references
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97929"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000144150"}]}]
centrosomelocated in
GO
2 publications
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0048"}]}]
  • ECO:0000314 PMID:17286961 ↗ IDA · UniProt · 20070807
    qualifier: located_in
  • ECO:0000314 PMID:21276791 ↗ IDA · UniProt · 20140220
    qualifier: located_in
cytosollocated in
GO
Evidence & references
  • ECO:0000304 Reactome:R-HSA-9709268 TAS · Reactome · 20201215
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9709273 TAS · Reactome · 20201211
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9763137 TAS · Reactome · 20201211
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9763200 TAS · Reactome · 20220201
    qualifier: located_in
secretory granulelocated in
GO
1 publication
Evidence & references
nuclear ubiquitin ligase complexpart of
GO
1 publication
Evidence & references
protein-containing complexpart of
GO
2 publications
Evidence & references
BRCA2-MAGE-D1 complexpart of
GO
1 publication
Evidence & references
DNA repair complexpart of
GO
1 publication
Evidence & references

Membrane topology 0

No annotation is recorded in this UniProt entry.

04

Disease & Variants

Source annotations; a recorded variant is not automatically a clinical classification.

Breast cancer BC

A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

Experimental evidence 26 publications
Evidence & references

Disease susceptibility is associated with variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Breast cancer",
    "diseaseAccession": "DI-02602",
    "acronym": "BC",
    "description": "A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "114480"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "10399947"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "10978364"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11139248"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11149425"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11241844"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11948477"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12145750"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12373604"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12442274"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12442275"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12569143"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12938098"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "14722926"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "15026808"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "15172753"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "15365993"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "16793542"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "17924331"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "23108138"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "24013206"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "29161300"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "8640237"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "9150152"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "9609997"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "9654203"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "9971877"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
      }
    ]
  }
}

Pancreatic cancer 2 PNCA2

A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Experimental evidence 1 publication
Evidence & references

The disease is caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Pancreatic cancer 2",
    "diseaseAccession": "DI-02847",
    "acronym": "PNCA2",
    "description": "A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "613347"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "9140390"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease is caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Breast-ovarian cancer, familial, 2 BROVCA2

A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.

Experimental evidence 4 publications
Evidence & references

Disease susceptibility is associated with variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Breast-ovarian cancer, familial, 2",
    "diseaseAccession": "DI-02603",
    "acronym": "BROVCA2",
    "description": "A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "612555"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "10584720"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11158174"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "7658781"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "9150155"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
      }
    ]
  }
}

Fanconi anemia complementation group D1 FANCD1

A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.

Experimental evidence 6 publications
Evidence & references

The disease is caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Fanconi anemia complementation group D1",
    "diseaseAccession": "DI-01601",
    "acronym": "FANCD1",
    "description": "A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "605724"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12065746"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "14670928"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "16825431"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "17924331"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "21719596"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "23108138"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease is caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Glioma 3 GLM3

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

Experimental evidence 1 publication
Evidence & references

The disease is caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Glioma 3",
    "diseaseAccession": "DI-02629",
    "acronym": "GLM3",
    "description": "Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "613029"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "15689453"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease is caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Medulloblastoma MDB

Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.

Experimental evidence 1 publication
Evidence & references

Disease susceptibility is associated with variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Medulloblastoma",
    "diseaseAccession": "DI-01958",
    "acronym": "MDB",
    "description": "Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "155255"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "29753700"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
      }
    ]
  }
}

Natural variants 160

Scroll across the table for evidence and actions.

160 recorded rows

FeaturePositionDescriptionEvidenceInspect
G25RVAR_02816725in BC; abolishes interaction with PALB2; dbSNP:rs80358961
G → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
W31CVAR_02816831in BC; abolishes interaction with PALB2; dbSNP:rs80359214
W → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
W31RVAR_02816931in BC; abolishes interaction with PALB2; dbSNP:rs80359182
W → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F32LVAR_00508532in BC; dbSNP:rs397508057 and dbSNP:rs1555280339
F → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Y42CVAR_02070542in BC and ovarian cancer; benign; dbSNP:rs4987046
Y → C
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
K53RVAR_00508653in BC; dbSNP:rs397507595
K → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N60SVAR_02070660in BC; uncertain significance; dbSNP:rs80358463
N → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T64IVAR_03271264in BC; dbSNP:rs397507615
T → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
A75PVAR_00508775in dbSNP:rs28897701
A → P
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F81LVAR_00508881in BC; dbSNP:rs80358507
F → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N108HVAR_008766108in dbSNP:rs80358567
N → H
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
R118HVAR_032713118in one patient with esophageal carcinoma; dbSNP:rs80358603
R → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M192TVAR_032714192in one patient with pancreatic cancer; dbSNP:rs80358805
M → T
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P201RVAR_005089201in BC; dbSNP:rs397507822
P → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V211AVAR_005090211in BC
V → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P222SVAR_005091222in BC; dbSNP:rs397507873
P → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T225AVAR_032715225in one patient with BC; normal RNA expression and splicing; dbSNP:rs80358897
T → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N289HVAR_005092289in dbSNP:rs766173
N → H
Experimental evidence 6 publications
Evidence & references
No verified residues in this structure
C315SVAR_032716315in one patient with esophageal carcinoma; dbSNP:rs79483201
C → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K322QVAR_018908322in dbSNP:rs11571640
K → Q
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
S326RVAR_032717326in BC; benign; dbSNP:rs28897706
S → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K327EVAR_008767327in BC; uncertain significance; dbSNP:rs80359242
K → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V355LVAR_005093355in lung cancer
V → L
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
N372HVAR_005094372in dbSNP:rs144848
N → H
Experimental evidence 9 publications
Evidence & references
No verified residues in this structure
G405RVAR_020707405in BC; uncertain significance
G → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T431IVAR_020708431in BC; uncertain significance; dbSNP:rs876660828
T → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R448HVAR_020709448in BC; uncertain significance; dbSNP:rs80358423
R → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E462GVAR_020710462in BC; benign; dbSNP:rs56403624
E → G
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
I505TVAR_032718505in BC; benign; dbSNP:rs28897708
I → T
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K513RVAR_056751513in dbSNP:rs28897709
K → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
C554WVAR_005095554in BC; benign; dbSNP:rs80358451
C → W
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T582PVAR_008768582in dbSNP:rs80358457
T → P
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T598AVAR_020711598in dbSNP:rs28897710
T → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S599FVAR_035436599in dbSNP:rs1046984
S → F
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P606LVAR_076440606in dbSNP:rs80358469
P → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L613RVAR_020712613in BC; uncertain significance; dbSNP:rs587780646
L → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T630IVAR_005096630in dbSNP:rs80358479
T → I
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
D707YVAR_008769707in dbSNP:rs80358487
D → Y
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
D728AVAR_005097728in BC; dbSNP:rs757577670
D → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
I729MVAR_032719729in BC; dbSNP:rs397507620
I → M
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M784VVAR_008770784in dbSNP:rs11571653
M → V
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
N886IVAR_008771886in dbSNP:rs80358526
N → I
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
L929SVAR_018909929in dbSNP:rs2227943
L → S
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
D935NVAR_008772935in BC; uncertain significance; dbSNP:rs28897716
D → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S976FVAR_018910976in dbSNP:rs11571656
S → F
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
I982LVAR_056752982in dbSNP:rs28897717
I → L
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
N987IVAR_018911987in dbSNP:rs2227944
N → I
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
N991DVAR_005098991in dbSNP:rs1799944
N → D
Experimental evidence 7 publications
Evidence & references
No verified residues in this structure
E1036KVAR_0207131036in BC; uncertain significance
E → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S1106RVAR_0207141106in BC; uncertain significance; dbSNP:rs1298550035
S → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N1147SVAR_0050991147in dbSNP:rs1799951
N → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S1172LVAR_0327201172in BC; benign; dbSNP:rs80358600
S → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S1179NVAR_0207151179in BC; dbSNP:rs397507674
S → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N1279SVAR_0207161279in dbSNP:rs1060502384
N → S
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Natural variantVAR_0087731286Natural variant
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
C1290YVAR_0087741290in dbSNP:rs41293485
C → Y
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Natural variantVAR_0051001302in BC
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
T1414MVAR_0087751414in dbSNP:rs70953664
T → M
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
D1420YVAR_0087761420in dbSNP:rs28897727
D → Y
Experimental evidence 6 publications
Evidence & references
No verified residues in this structure
K1445TVAR_0207171445in BC; uncertain significance
K → T
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D1513NVAR_0087771513in dbSNP:rs80358687
D → N
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
L1522FVAR_0327211522in one patient with BC; dbSNP:rs397507729
L → F
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F1524VVAR_0207181524in BC; benign; dbSNP:rs56386506
F → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
G1529RVAR_0051011529in dbSNP:rs28897728
G → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
V1542MVAR_0567531542in dbSNP:rs28897729
V → M
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
H1561NVAR_0189121561in dbSNP:rs2219594
H → N
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
C1580YVAR_0207191580in BC; somatic mutation; dbSNP:rs398122784
C → Y
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1593DVAR_0087781593in dbSNP:rs80358703
E → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V1643AVAR_0567541643in dbSNP:rs28897731
V → A
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
T1679IVAR_0207201679in BC
T → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K1690NVAR_0327221690in BC; benign; dbSNP:rs56087561
K → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N1730YVAR_0327231730in BC; dbSNP:rs397507770
N → Y
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
G1771DVAR_0087791771in BC; benign; dbSNP:rs80358755
G → D
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
V1804AVAR_0207211804in BC; dbSNP:rs370252983
V → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N1805SVAR_0087801805in dbSNP:rs80358765
N → S
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
N1880KVAR_0051021880in dbSNP:rs11571657
N → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T1887MVAR_0327241887in BC; dbSNP:rs397507795
T → M
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1901KVAR_0207221901in BC
E → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D1902NVAR_0087811902in dbSNP:rs4987048
D → N
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
T1915MVAR_0051031915in dbSNP:rs4987117
T → M
Experimental evidence 5 publications
Evidence & references
No verified residues in this structure
I1929VVAR_0207231929in BC; benign; dbSNP:rs79538375
I → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S1979RVAR_0567551979in dbSNP:rs28897737
S → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
V1988IVAR_0327251988in one patient with esophageal carcinoma; somatic mutation; dbSNP:rs28897739
V → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T2031AVAR_0207242031in BC; uncertain significance
T → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R2034CVAR_0051042034in dbSNP:rs1799954
R → C
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
G2044VVAR_0327262044in one patient with BC; dbSNP:rs56191579
G → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S2072CVAR_0207252072in BC; dbSNP:rs80358862
S → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H2074NVAR_0087822074in dbSNP:rs34309943
H → N
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
E2089DVAR_0087832089in BC
E → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Y2094CVAR_0207262094in BC; dbSNP:rs397507838
Y → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P2096LVAR_0207272096in BC
P → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R2108CVAR_0327272108in dbSNP:rs55794205
R → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H2116RVAR_0615632116in dbSNP:rs55953736
H → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
V2118LVAR_0207282118in BC; uncertain significance
V → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K2128NVAR_0207292128in BC; dbSNP:rs397507847
K → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N2135HVAR_0327282135in BC; dbSNP:rs80358876
N → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V2138FVAR_0087842138in dbSNP:rs11571659
V → F
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
K2162RVAR_0189132162in dbSNP:rs11571660
K → R
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
Y2222CVAR_0327292222in BC; dbSNP:rs397507875
Y → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D2238EVAR_0567562238in dbSNP:rs28897742
D → E
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
G2274VVAR_0051052274in BC; dbSNP:rs55712212
G → V
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
E2275GVAR_0207302275in BC; uncertain significance
E → G
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F2293LVAR_0207312293in BC; uncertain significance; dbSNP:rs80358912 and dbSNP:rs1381512588
F → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R2336HVAR_0327302336in FANCD1; affects protein splicing and expression; decreases homologous recombination-mediated DNA repair; dbSNP:rs28897743
R → H
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
R2336QVAR_0567572336in dbSNP:rs28897743
R → Q
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
G2353RVAR_0207322353in BC; benign; dbSNP:rs80358935
G → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H2415NVAR_0051062415in BC
H → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q2421HVAR_0051072421in BC
Q → H
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
H2440RVAR_0189142440no effect on homology-directed repair activity; dbSNP:rs4986860
H → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N2447DVAR_0567582447in dbSNP:rs4986859
N → D
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Q2456EVAR_0327312456in BC; dbSNP:rs397507912
Q → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V2466AVAR_0087852466in BC; benign; no effect on homology-directed repair activity; dbSNP:rs169547
V → A
Experimental evidence 7 publications
Evidence & references
No verified residues in this structure
L2480VVAR_0087862480in dbSNP:rs80358965
L → V
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
R2488KVAR_0207332488in BC; uncertain significance; dbSNP:rs80358968
R → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
I2490TVAR_0087872490no effect on homologous recombination-mediated DNA repair; no effect on interaction with SEM1; dbSNP:rs11571707
I → T
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R2502CVAR_0639112502in BC; uncertain significance; dbSNP:rs55716624
R → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R2502HVAR_0087882502in dbSNP:rs56070345
R → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L2510PVAR_0327322510in FANCD1; hypersensitive to DNA damage; disrupts interaction with SEM1; decreased homology-directed repair activity; dbSNP:rs80358979
L → P
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
T2515IVAR_0087892515in BC; benign; dbSNP:rs28897744
T → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
W2626CVAR_0327332626in FANCD1; hypersensitive to DNA damage; reduced homology-directed repair activity; no effect on interaction with SEM1; dbSNP:rs80359013
W → C
Experimental evidence 4 publications
Evidence & references
No verified residues in this structure
I2627FVAR_0639122627in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs80359014
I → F
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
L2653PVAR_0639132653in BC; uncertain significance; reduced homology-directed repair activity; dbSNP:rs80359022
L → P
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
R2659KVAR_0639142659in BC; uncertain significance; dbSNP:rs80359027
R → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E2663VVAR_0639152663in BC; pathogenic; major splicing aberration identified with this mutant; dbSNP:rs80359031
E → V
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
L2686PVAR_0567592686in dbSNP:rs28897746
L → P
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
N2706SVAR_0207342706in dbSNP:rs80359055
N → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T2722RVAR_0186612722in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs80359062
T → R
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
D2723GVAR_0639162723in BC; pathogenic; major splicing aberration identified with this mutant; reduced homology-directed repair activity; dbSNP:rs41293513
D → G
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
D2723HVAR_0207352723in BC; pathogenic; disrupts interaction with SEM1 promoting interaction with XPO1 and BRCA2 cytoplasmic localization; in heterozygous state promotes RAD51 cytoplasmic localization; reduced homology-directed repair activity; dbSNP:rs41293511
D → H
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
V2728IVAR_0207362728in BC; benign; dbSNP:rs28897749
V → I
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
K2729NVAR_0207372729in BC; benign; no effect on homologous recombination-mediated DNA repair; no effect on interaction with SEM1; dbSNP:rs80359065
K → N
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
G2748DVAR_0639172748in BC; pathogenic; dbSNP:rs80359071
G → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R2787HVAR_0087902787in BC; uncertain significance; also found in ovarian cancer; uncertain significance; somatic mutation; small decrease of homology-directed repair activity; dbSNP:rs80359078
R → H
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
L2792PVAR_0567602792in BC; uncertain significance; decreased homology-directed repair activity; dbSNP:rs28897751
L → P
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
G2793RVAR_0207382793in BC; uncertain significance; decreased homology-directed repair activity; dbSNP:rs80359082
G → R
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
S2835PVAR_0189152835in dbSNP:rs11571746
S → P
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
R2842CVAR_0327342842in one patient with esophageal carcinoma; somatic mutation; decreased homology-directed repair activity; dbSNP:rs80359104
R → C
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
E2856AVAR_0189162856in BC; uncertain significance; no effect on homology-directed repair activity; dbSNP:rs11571747
E → A
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
I2944FVAR_0087912944in dbSNP:rs4987047
I → F
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K2950NVAR_0207392950in BC; uncertain significance; dbSNP:rs28897754
K → N
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
A2951TVAR_0087922951in BC; benign; no effect on homology-directed repair activity; dbSNP:rs11571769
A → T
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
V2969MVAR_0087932969in dbSNP:rs59004709
V → M
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
T3013IVAR_0207403013in BC; benign; no effect on homology-directed repair activity; dbSNP:rs28897755
T → I
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
R3052WVAR_0639183052in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs45580035
R → W
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
P3063SVAR_0207413063in a patient with ovarian cancer; uncertain significance; no effect on homology-directed repair activity; dbSNP:rs80359176
P → S
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
G3076EVAR_0207423076in BC; also found in pancreatic cancer; decreased homology-directed repair activity; dbSNP:rs80359187
G → E
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
D3095EVAR_0051083095in BC; uncertain significance; reduced homology-directed repair activity; dbSNP:rs80359198
D → E
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
Y3098HVAR_0087943098in BC and ovarian cancer; benign; no effect on homology-directed repair activity; dbSNP:rs41293521
Y → H
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
L3101RVAR_0567613101in dbSNP:rs28897758
L → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
I3103MVAR_0051093103in melanoma; dbSNP:rs80359204
I → M
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
M3118TVAR_0051103118in BC; dbSNP:rs56204128
M → T
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N3124IVAR_0207433124in BC; pathogenic; reduced homology-directed repair activity; dbSNP:rs28897759
N → I
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
K3196EVAR_0207443196in BC; dbSNP:rs80359228
K → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V3244IVAR_0189173244in dbSNP:rs11571831
V → I
Experimental evidence
Evidence & references
  • ECO:0000269 Reference:Ref.3
No verified residues in this structure
K3257RVAR_0087953257in dbSNP:rs55847618
K → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
R3276SVAR_0087963276in dbSNP:rs80359245
R → S
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
P3300SVAR_0327353300in one patient with esophageal carcinoma; dbSNP:rs770868371
P → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T3357RVAR_0051113357in BC; dbSNP:rs80358388
T → R
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
T3374IVAR_0207453374in dbSNP:rs56309455
T → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
I3412VVAR_0051123412in dbSNP:rs1801426
I → V
Experimental evidence 7 publications
Evidence & references
No verified residues in this structure

Laboratory mutagenesis 12

Scroll across the table for evidence and actions.

12 recorded rows

FeaturePositionDescriptionEvidenceInspect
R2401A2401Decreased interaction with DMC1.
R → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K2404A2404Decreased interaction with DMC1.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
FVPP2406AVPA2406–2409Abolished interaction with DMC1.
FVPP → AVPA
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F2406A2406Abolished interaction with DMC1.
F → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P2408A2408Abolished interaction with DMC1.
P → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P2409A2409Abolished interaction with DMC1.
P → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
KTK2411ATA2411–2413Abolished interaction with DMC1.
KTK → ATA
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K2411A2411Does not affect interaction with DMC1.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K2413A2413Does not affect interaction with DMC1.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
W2725A2725Disrupts interaction with SEM1.
W → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S3291E3291Impaired interaction with RAD51.
S → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T3387A3387Loss of phosphorylation by CHEK1 and CHEK2 (in vitro).
T → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
05

PTM/Processing

Phosphorylated by ATM upon irradiation-induced DNA damage [13]. Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51 [26]. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51-binding [17, 23]

Experimental evidence 4 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15199141"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15800615"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515903"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18317453"
        }
      ],
      "value": "Phosphorylated by ATM upon irradiation-induced DNA damage (PubMed:15199141). Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51 (PubMed:18317453). Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51-binding (PubMed:15800615, PubMed:17515903)"
    }
  ],
  "commentType": "PTM"
}

Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation [14]. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation [14]

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15314155"
        }
      ],
      "value": "Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation (PubMed:15314155). In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation (PubMed:15314155)"
    }
  ],
  "commentType": "PTM"
}

Processed chains & precursor regions 1

Scroll across the table for evidence and actions.

1 recorded rows

FeaturePositionDescriptionEvidenceInspect
ChainPRO_00000649841–3418Breast cancer type 2 susceptibility protein
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure

Modifications 10

Scroll across the table for evidence and actions.

10 recorded rows

FeaturePositionDescriptionEvidenceInspect
Modified residue70Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue445Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue492Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue755Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue1970Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue2035Phosphothreonine
1 publication
Evidence & references
No verified residues in this structure
Modified residue2095Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue3291Phosphoserine; by CDK1 and CDK2
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Modified residue3319Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue3387Phosphothreonine; by CHEK1 and CHEK2
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
06

Expression

Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "8589730"
        }
      ],
      "value": "Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen"
    }
  ],
  "commentType": "TISSUE SPECIFICITY"
}
07

Interaction

Documented interaction partners

UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.

13 records
Partner / productSpeciesExperimentsEvidence & actions
BRCA2P51587With P51587Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: P51587. Reported experiment count: 3.

Open protein ↗
DMC1Q14565With P51587Homo sapiens12
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q14565. Reported experiment count: 12.

Open protein ↗
FANCD2Q9BXW9With P51587Homo sapiens16
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q9BXW9. Reported experiment count: 16.

Open protein ↗
FANCD2Q9BXW9-2With P51587Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q9BXW9-2. Reported experiment count: 3.

Open protein ↗
HMG20BQ9P0W2With P51587Homo sapiens8
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q9P0W2. Reported experiment count: 8.

Open protein ↗
MAP1LC3BQ9GZQ8With P51587Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q9GZQ8. Reported experiment count: 2.

Open protein ↗
PALB2Q86YC2With P51587Homo sapiens30
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q86YC2. Reported experiment count: 30.

Open protein ↗
PDS5BQ9NTI5With P51587Homo sapiens26
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q9NTI5. Reported experiment count: 26.

Open protein ↗
POLHQ9Y253With P51587Homo sapiens6
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q9Y253. Reported experiment count: 6.

Open protein ↗
RAD51Q06609With P51587Homo sapiens46
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q06609. Reported experiment count: 46.

Open protein ↗
RAD51Q06609-1With P51587Homo sapiens12
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: Q06609-1. Reported experiment count: 12.

Open protein ↗
SEM1P60896With P51587Homo sapiens10
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: P60896. Reported experiment count: 10.

Open protein ↗
TP53P04637With P51587Homo sapiens7
IntAct evidence

Pair evidence in IntAct ↗

Source product: P51587. Partner: P04637. Reported experiment count: 7.

Open protein ↗

Complex membership & assembly descriptions

Co-membership does not by itself prove direct binding between every pair.

BRCA1-PALB2-BRCA2 homologous recombination DNA repair complex CPX-845 Complex Portal

Homo sapiens; 9606 ·

Evidence: physical interaction evidence

  • PALB2 · Q86YC2 · minValue: 1, maxValue: 1
  • BRCA1 · P38398 ·
  • BRCA2 · P51587 · minValue: 1, maxValue: 1

Potentiates homologoues recombinational DNA repair (HR) by promoting assembly of RAD51 family of DNA repair proteins onto newly synthesized single-stranded DNA. Act downstream of Fanconi anemia proteins and complexes to repair DNA interstrand crosslinks. The MRN complex (CPX-4442) recruits ATM (Q13315) to the site of double-stranded DNA breaks, which then auto-activates and recruits BRCA1, facilitating a shift from non-homologous end-joining to HR. A newly generated single-strand of DNA is covered by replication protein A (RPA) complex (CPX-1878/CPX-1879). PALB2 is phosphorylated on Ser-59 by ATR (Q13535) and the BRCA1-PALB2-BRCA2 complex forms, promoting RPA removal and RAD51 loading. The resulting RAD51-ssDNA filament invades the intact sister chromatid and the strand is extended through the action of DNA polymerases.

Source & references ↗
BRCC E3 ubiquitin ligase complex CPX-955 Complex Portal

Homo sapiens; 9606 ·

Evidence: inferred by curator

  • RAD51 · Q06609 ·
  • BRCA1 · P38398 ·
  • BARD1 · Q99728 ·
  • BRCC3 · P46736 ·
  • BRCA2 · P51587 ·
  • BABAM2 · Q9NXR7 ·

A Ubc5-dependent E3 ubiquitin ligase complex involved in DNA repair, potentially by regulating factors involved in the process. It has a defined substrate specificity, with a strong preference for the nucleosome core histones H2A, H2B, H3 and H4. It co-localizes with, and efficiently ubiquitylates, the histone variant H2AX at sites of DNA damage.

Source & references ↗

UniProt subunit description

Monomer and dimer [30]. Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair [11, 47, 17, 18, 22, 23, 26, 27, 32, 29, 31, 40, 46]. Interacts with DMC1; regulates DMC1 recruitment and function at sites of meiotic double-strand breaks (DSBs) [32, 42, 50, 49].

Interacts with WDR16, USP11, DMC1, ROCK2 and NPM1 [14, 19, 33]. Interacts with SEM1; the interaction masks a nuclear export signal in BRCA2 [9, 21, 94, 36]. Interacts with both non-ubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG [12, 13, 25].

Part of a BRCA complex containing BRCA1, BRCA2 and PALB2 [28]. Component of the homologous recombination repair (HR) complex composed of ERCC5/XPG, BRCA2, PALB2, DSS1 and RAD51 [41]. Within the complex, interacts with ERCC5/XPG and PALB2 [41].

Interacts directly with PALB2 which may serve as a scaffold for a HR complex containing PALB2, BRCA2, RAD51C, RAD51 and XRCC3 [20, 28, 48, 37, 41, 43]. Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein [28]. Interacts with POLH; the interaction is direct [38].

Interacts with the TREX-2 complex subunits PCID2 and SEM1 [94, 39]. Interacts with HSF2BP and BRME1; the interaction with HSF2BP is direct and allows the formation of a ternary complex [44]. The complex BRME1:HSF2BP:BRCA2 interacts with SPATA22, MEIOB and RAD51 (By similarity)

By similarityExperimental evidence 35 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P97929"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10373512"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11239456"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12442171"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15115758"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15199141"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15314155"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15800615"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15937124"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15967112"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "16205630"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "16793542"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515903"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515904"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18212739"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18317453"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19303847"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19369211"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19609323"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20729832"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20729858"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20729859"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21076401"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21084279"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21719596"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24013206"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24141787"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24485656"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24896180"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "26833090"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27941124"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "28319063"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "31242413"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "37499663"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "38828772"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "39333100"
        }
      ],
      "value": "Monomer and dimer (PubMed:20729858). Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair (PubMed:11239456, PubMed:12442171, PubMed:15800615, PubMed:15937124, PubMed:17515904, PubMed:17515903, PubMed:18317453, PubMed:19303847, PubMed:20729832, PubMed:20729859, PubMed:21076401, PubMed:27941124, PubMed:37499663). Interacts with DMC1; regulates DMC1 recruitment and function at sites of meiotic double-strand breaks (DSBs) (PubMed:20729832, PubMed:26976601, PubMed:38828772, PubMed:39333100). Interacts with WDR16, USP11, DMC1, ROCK2 and NPM1 (PubMed:15314155, PubMed:15967112, PubMed:21084279). Interacts with SEM1; the interaction masks a nuclear export signal in BRCA2 (PubMed:10373512, PubMed:16205630, PubMed:21719596, PubMed:24013206). Interacts with both non-ubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG (PubMed:15115758, PubMed:15199141, PubMed:18212739). Part of a BRCA complex containing BRCA1, BRCA2 and PALB2 (PubMed:19369211). Component of the homologous recombination repair (HR) complex composed of ERCC5/XPG, BRCA2, PALB2, DSS1 and RAD51 (PubMed:26833090). Within the complex, interacts with ERCC5/XPG and PALB2 (PubMed:26833090). Interacts directly with PALB2 which may serve as a scaffold for a HR complex containing PALB2, BRCA2, RAD51C, RAD51 and XRCC3 (PubMed:16793542, PubMed:19369211, PubMed:19609323, PubMed:24141787, PubMed:26833090, PubMed:28319063). Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein (PubMed:19369211). Interacts with POLH; the interaction is direct (PubMed:24485656). Interacts with the TREX-2 complex subunits PCID2 and SEM1 (PubMed:21719596, PubMed:24896180). Interacts with HSF2BP and BRME1; the interaction with HSF2BP is direct and allows the formation of a ternary complex (PubMed:31242413). The complex BRME1:HSF2BP:BRCA2 interacts with SPATA22, MEIOB and RAD51 (By similarity)"
    }
  ],
  "commentType": "SUBUNIT"
}

Other association resources

Resource links only; their association networks and counts are not added to the partner table.

08

Structure

8C3N · Stapled peptide SP30 in complex with humanised RadA mutant HumRadA22

X-RAY DIFFRACTION · 1.21 Å

Recorded components

ComponentSpeciesChainsProtein identities
DNA repair and recombination protein RadAprotein · Entity 1Pyrococcus furiosusAO74036
Breast cancer type 2 susceptibility proteinprotein · Entity 2Homo sapiensBP51587
ADENOSINE-5'-DIPHOSPHATEligand · Entity 3CNo verified protein mapping
MAGNESIUM IONligand · Entity 4DNo verified protein mapping
4,6-diethylpyrimidin-2-amineligand · Entity 5ENo verified protein mapping

Biological assemblies

Assembly 1 · author_and_software_defined_assembly
Recorded chains: A, B, C, D, E

Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.

Publication

A recombinant approach for stapled peptide discovery yields inhibitors of the RAD51 recombinase.

21/11/2023 · Read publication ↗

Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.

PDB source record ↗

Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.

Available structures 14

Scroll across the table for evidence and actions.

14 recorded rows

RecordEvidence typeMethodResolutionOpen
8C3NexperimentalX-ray1.21 AOpen in Atlas ↗
8BR9experimentalX-ray1.63 AOpen in Atlas ↗
1N0WexperimentalX-ray1.70 AOpen in Atlas ↗
6HQUexperimentalX-ray1.97 AOpen in Atlas ↗
3EU7experimentalX-ray2.20 AOpen in Atlas ↗
7LDGexperimentalX-ray2.56 AOpen in Atlas ↗
7BDXexperimentalX-ray2.60 AOpen in Atlas ↗
8PBCexperimentalEM2.61 AOpen in Atlas ↗
8UVWexperimentalX-ray2.73 AOpen in Atlas ↗
8PBDexperimentalEM2.83 AOpen in Atlas ↗
8C3JexperimentalX-ray3.02 AOpen in Atlas ↗
6GY2experimentalX-ray3.11 AOpen in Atlas ↗
8QQEexperimentalX-ray3.46 AOpen in Atlas ↗
8R2GexperimentalX-ray3.45 AOpen in Atlas ↗
09

Family & Domains

Interacts with DMC1 and RAD51 through its eight BRCA2 repeats and its C-terminal TR2 region [18, 23, 22, 27]. The BRCA2 repeats promote RAD51 nucleation on single-stranded DNA (ssDNA) [27]. The TR2 region stabilizes RAD51 oligomers already assembled on ssDNA [23, 22]

Experimental evidence 4 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15937124"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515903"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17515904"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19303847"
        }
      ],
      "value": "Interacts with DMC1 and RAD51 through its eight BRCA2 repeats and its C-terminal TR2 region (PubMed:15937124, PubMed:17515903, PubMed:17515904, PubMed:19303847). The BRCA2 repeats promote RAD51 nucleation on single-stranded DNA (ssDNA) (PubMed:19303847). The TR2 region stabilizes RAD51 oligomers already assembled on ssDNA (PubMed:17515903, PubMed:17515904)"
    }
  ],
  "commentType": "DOMAIN"
}

Domain architecture

Canonical sequence13418 aa

Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.

Atlas domains, motifs & repeats 15

Scroll across the table for evidence and actions.

15 recorded rows

AnnotationPositionSource & interpretationInspect
BRCA2 repeatIPR0020931002–1036INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020931212–1246INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020931421–1455INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020931517–1551INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020931664–1698INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020931837–1871INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020931971–2005INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
BRCA2 repeatIPR0020932051–2085INTERPROrepeat

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage.

Full source description

The breast cancer type 2 susceptibility protein has a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment. BRCA2 is a breast tumour suppressor with a potential function in the cellular response to DNA damage. At the cellular level, expression is regulated in a cell-cycle dependent manner and peak expression of BRCA2 mRNA is found in S phase, suggesting BRCA2 may participate in regulating cell proliferation. There are eight repeats in BRCA2 designated as BRC1 to BRC8. BRC1, BRC2, BRC3, BRC4, BRC7, and BRC8 are highly conserved and bind to Rad51, whereas BRC5 and BRC6 are less well conserved and do not bind to Rad51. It has been suggested that BRCA2 plays a role in positioning Rad51 at the site of DNA repair or in removing Rad51 from DNA once repair has been completed.

Source entry ↗
No verified residues in this structure
Breast cancer type 2 susceptibility protein, helical domainIPR0152522482–2667INTERPROdomain

This entry represents a domain found in BRCA2 proteins. This domain adopts a helical structure, consisting of a four-helix cluster core (α1, α8, α9, α10) and two successive β-hairpins (β1 to β4).

Full source description

This entry represents a domain found in BRCA2 proteins. This domain adopts a helical structure, consisting of a four-helix cluster core (α1, α8, α9, α10) and two successive β-hairpins (β1 to β4). An approximately 50-amino acid segment that contains four short helices (α2 to α4), meanders around the surface of the core structure. In BRCA2, the α9 and α10 helices pack with BRCA-2_OB1 ([interpro:IPR015187]) through van der Waals contacts involving hydrophobic and aromatic residues, and also through side-chain and backbone hydrogen bonds. This domain binds the 70-amino acid DSS1 (deleted in split-hand/split foot syndrome) protein, which was originally identified as one of three genes that map to a 1.5-Mb locus deleted in an inherited developmental malformation syndrome.

Source entry ↗
No verified residues in this structure
BRCA2, OB1IPR0151872670–2795INTERPROdomain

No description available for this entry.

Source entry ↗
No verified residues in this structure
BRCA2, OB2 domainIPR0482622804–3054INTERPROdomain

This entry corresponds to the second OB fold domain (OB2) of BRCA2 (breast cancer susceptibility gene 2) protein. BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks.

Full source description

This entry corresponds to the second OB fold domain (OB2) of BRCA2 (breast cancer susceptibility gene 2) protein. BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. It stimulates the displacement of Replication protein A (RPA), the most abundant eukaryotic ssDNA binding protein. It also facilitates filament formation. Mutations that map throughout the BRCA2 protein are associated with breast cancer susceptibility. BRCA2 is a large nuclear protein and its most conserved region is the C-terminal. This region binds to ssDNA in vitro, and is composed of five structural domains, three of which are OB folds (OB1, OB2, and OB3). OB2 contains a large insertion, named tower domain that is represented separately by [interpro:IPR015205] but included in this entry.

Source entry ↗
No verified residues in this structure
Tower domainIPR0152052831–2872INTERPROdomain

This domain adopts a secondary structure consisting of a pair of long, antiparallel α-helices (the stem) that support a three-helix bundle (3HB) at their end. The 3HB contains a helix-turn-helix motif and is similar to the DNA binding domains of the bacterial site-specific recombinases, and of eukaryotic Myb and homeodomain transcription factors.

Full source description

This domain adopts a secondary structure consisting of a pair of long, antiparallel α-helices (the stem) that support a three-helix bundle (3HB) at their end. The 3HB contains a helix-turn-helix motif and is similar to the DNA binding domains of the bacterial site-specific recombinases, and of eukaryotic Myb and homeodomain transcription factors. The Tower domain has an important role in the tumour suppressor function of BRCA2, and is essential for appropriate binding of BRCA2 to DNA.

Source entry ↗
No verified residues in this structure
BRCA2, OB2PF213182969–3035PFAMdomain

BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. t stimulates the displacement of Replication protein A (RPA), and also facilitates filament formation.

Full source description

BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. t stimulates the displacement of Replication protein A (RPA), and also facilitates filament formation. This entry represents the second OB fold (OB2) from the C-terminal ssDNA binding domain (DBD) which has three OB folds. OB2 and OB3 are arranged in tandem and their mode of binding can be considered qualitatively similar to two OB folds of RPA1, DBD-A and DBD-B.

Source entry ↗
No verified residues in this structure
BRCA2, OB3IPR0151883052–3185INTERPROdomain

BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. It stimulates the displacement of Replication protein A (RPA), the most abundant eukaryotic ssDNA binding protein.

Full source description

BRCA2 participates in homologous recombination-mediated repair of double-strand DNA breaks. It stimulates the displacement of Replication protein A (RPA), the most abundant eukaryotic ssDNA binding protein. Mutations that map throughout the BRCA2 protein are associated with breast cancer susceptibility. BRCA2 is a large nuclear protein and its most conserved region is the C-terminal BRCA2DBD. BRCA2DBD binds ssDNA in vitro, and is composed of five structural domains, three of which are OB folds (OB1, OB2, and OB3). BRCA2DBD OB2 and OB3 are arranged in tandem, and their mode of binding can be considered qualitatively similar to two OB folds of RPA1, DBD-A and DBD-B (the major DBDs of RPA). This entry represents OB3, which consists of a highly curved five-stranded β-sheet that closes on itself to form a β-barrel. OB3 has a pronounced groove formed by one face of the curved sheet and is demarcated by two loops, one between β1 and β2 and another between β4 and β5, which allows for strong ssDNA binding.

Source entry ↗
No verified residues in this structure
BRCA2, TR2 domainIPR0550773260–3334INTERPROdomain

This domain is found near the C terminus of BRCA2 and similar proteins from vertebrates. It is likely that the TR2 domain is largely disordered and does not fold into a globular structure.

Full source description

This domain is found near the C terminus of BRCA2 and similar proteins from vertebrates. It is likely that the TR2 domain is largely disordered and does not fold into a globular structure. It contains a highly conserved proline-rich region which is preceded by a conserved stretch of positively charged residues. This domain is known to interact with meiosis-specific recombinase DMC1 and RAD51.

Source entry ↗
No verified residues in this structure

UniProt domains, repeats & motifs 9

Scroll across the table for evidence and actions.

9 recorded rows

FeaturePositionDescriptionEvidenceInspect
Repeat1002–1036BRCA2 1
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat1212–1246BRCA2 2
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat1421–1455BRCA2 3
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat1517–1551BRCA2 4
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat1664–1698BRCA2 5
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat1837–1871BRCA2 6
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat1971–2005BRCA2 7
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat2051–2085BRCA2 8
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Motif2682–2698Nuclear export signal; masked by interaction with SEM1
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure

Functional sites 0

No annotation is recorded in this UniProt entry.

Sequence regions 14

Scroll across the table for evidence and actions.

14 recorded rows

FeaturePositionDescriptionEvidenceInspect
Region1–40Interaction with PALB2
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Region37–68Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region358–381Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region639–1000Interaction with NPM1
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Region1003–2082Interaction with RAD51
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P97929
No verified residues in this structure
Region1338–1781Interaction with POLH
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Region1410–1595Required for stimulation of POLH DNA polymerization activity
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Region2270–2337Interaction with HSF2BP
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Region2350–2545Interaction with FANCD2
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Region2430–2450Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region2481–2832Interaction with SEM1
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Region3265–3330TR2 region
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Region3393–3418Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias2430–2450Basic and acidic residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
10

Sequence & Isoforms

Sequence & isoforms

UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.

UniProt’s canonical sequence · P515873418 aa384,230 Da · source sequence mass

The mass describes this unmodified source sequence, not every mature or modified product.

MPIGSKERPTFFEIFKTRCNKADLGPISLNWFEELSSEAPPYNSEPAEESEHKNNNYEPNLFKTPQRKPSYNQLASTPIIFKEQGLTLPLYQSPVKELDKFKLDLGRNVPNSRHKSLRTVKTKMDQADDVSCPLLNSCLSESPVVLQCTHVTPQRDKSVVCGSLFHTPKFVKGRQTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLIVRNEEASETVFPHDTTANVKSYFSNHDESLKKNDRFIASVTDSENTNQREAASHGFGKTSGNSFKVNSCKDHIGKSMPNVLEDEVYETVVDTSEEDSFSLCFSKCRTKNLQKVRTSKTRKKIFHEANADECEKSKNQVKEKYSFVSEVEPNDTDPLDSNVANQKPFESGSDKISKEVVPSLACEWSQLTLSGLNGAQMEKIPLLHISSCDQNISEKDLLDTENKRKKDFLTSENSLPRISSLPKSEKPLNEETVVNKRDEEQHLESHTDCILAVKQAISGTSPVASSFQGIKKSIFRIRESPKETFNASFSGHMTDPNFKKETEASESGLEIHTVCSQKEDSLCPNLIDNGSWPATTTQNSVALKNAGLISTLKKKTNKFIYAIHDETSYKGKKIPKDQKSELINCSAQFEANAFEAPLTFANADSGLLHSSVKRSCSQNDSEEPTLSLTSSFGTILRKCSRNETCSNNTVISQDLDYKEAKCNKEKLQLFITPEADSLSCLQEGQCENDPKSKKVSDIKEEVLAAACHPVQHSKVEYSDTDFQSQKSLLYDHENASTLILTPTSKDVLSNLVMISRGKESYKMSDKLKGNNYESDVELTKNIPMEKNQDVCALNENYKNVELLPPEKYMRVASPSRKVQFNQNTNLRVIQKNQEETTSISKITVNPDSEELFSDNENNFVFQVANERNNLALGNTKELHETDLTCVNEPIFKNSTMVLYGDTGDKQATQVSIKKDLVYVLAEENKNSVKQHIKMTLGQDLKSDISLNIDKIPEKNNDYMNKWAGLLGPISNHSFGGSFRTASNKEIKLSEHNIKKSKMFFKDIEEQYPTSLACVEIVNTLALDNQKKLSKPQSINTVSAHLQSSVVVSDCKNSHITPQMLFSKQDFNSNHNLTPSQKAEITELSTILEESGSQFEFTQFRKPSYILQKSTFEVPENQMTILKTTSEECRDADLHVIMNAPSIGQVDSSKQFEGTVEIKRKFAGLLKNDCNKSASGYLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISLSSSKCHDSVVSMFKIENHNDKTVSEKNNKCQLILQNNIEMTTGTFVEEITENYKRNTENEDNKYTAASRNSHNLEFDGSDSSKNDTVCIHKDETDLLFTDQHNICLKLSGQFMKEGNTQIKEDLSDLTFLEVAKAQEACHGNTSNKEQLTATKTEQNIKDFETSDTFFQTASGKNISVAKESFNKIVNFFDQKPEELHNFSLNSELHSDIRKNKMDILSYEETDIVKHKILKESVPVGTGNQLVTFQGQPERDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEITSFSHQWAKTLKYREACKDLELACETIEITAAPKCKEMQNSLNNDKNLVSIETVVPPKLLSDNLCRQTENLKTSKSIFLKVKVHENVEKETAKSPATCYTNQSPYSVIENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIFDGQPERINTADYVGNYLYENNSNSTIAENDKNHLSEKQDTYLSNSSMSNSYSYHSDEVYNDSGYLSKNKLDSGIEPVLKNVEDQKNTSFSKVISNVKDANAYPQTVNEDICVEELVTSSSPCKNKNAAIKLSISNSNNFEVGPPAFRIASGKIVCVSHETIKKVKDIFTDSFSKVIKENNENKSKICQTKIMAGCYEALDDSEDILHNSLDNDECSTHSHKVFADIQSEEILQHNQNMSGLEKVSKISPCDVSLETSDICKCSIGKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQVFSKVLFKSNEHSDQLTREENTAIRTPEHLISQKGFSYNVVNSSAFSGFSTASGKQVSILESSLHKVKGVLEEFDLIRTEHSLHYSPTSRQNVSKILPRVDKRNPEHCVNSEMEKTCSKEFKLSNNLNVEGGSSENNHSIKVSPYLSQFQQDKQQLVLGTKVSLVENIHVLGKEQASPKNVKMEIGKTETFSDVPVKTNIEVCSTYSKDSENYFETEAVEIAKAFMEDDELTDSKLPSHATHSLFTCPENEEMVLSNSRIGKRRGEPLILVGEPSIKRNLLNEFDRIIENQEKSLKASKSTPDGTIKDRRLFMHHVSLEPITCVPFRTTKERQEIQNPNFTAPGQEFLSKSHLYEHLTLEKSSSNLAVSGHPFYQVSATRNEKMRHLITTGRPTKVFVPPFKTKSHFHRVEQCVRNINLEENRQKQNIDGHGSDDSKNKINDNEIHQFNKNNSNQAVAVTFTKCEEEPLDLITSLQNARDIQDMRIKKKQRQRVFPQPGSLYLAKTSTLPRISLKAAVGGQVPSACSHKQLYTYGVSKHCIKINSKNAESFQFHTEDYFGKESLWTGKGIQLADGGWLIPSNDGKAGKEEFYRALCDTPGVDPKLISRIWVYNHYRWIIWKLAAMECAFPKEFANRCLSPERVLLQLKYRYDTEIDRSRRSAIKKIMERDDTAAKTLVLCVSDIISLSANISETSSNKTSSADTQKVAIIELTDGWYAVKAQLDPPLLAVLKNGRLTVGQKIILHGAELVGSPDACTPLEAPESLMLKISANSTRPARWYTKLGFFPDPRPFPLPLSSLFSDGGNVGCVDVIIQRAYPIQWMEKTSSGLYIFRNEREEEKEAAKYVEAQQKRLEALFTKIQEEFEEHEENTTKPYLPSRALTRQQVRALQDGAELYEAVKNAADPAYLEGYFSEEQLRALNNHRQMLNDKKQAQIQLEIRKAMESAEQKEQGLSRDVTTVWKLRIVSYSKKEKDSVILSIWRPSSDLYSLLTEGKRYRIYHLATSKSKSKSERANIQLAATKKTQYQQLPVSDEILFQIYQPREPLHFSKFLDPDFQPSCSEVDLIGFVVSVVKKTGLAPFVYLSDECYNLLAIKFWIDLNEDIIKPHMLIAASNLQWRPESKSGLLTLFAGDFSVFSASPKEGHFQETFNKMKNTVENIDILCNEAENKLMHILHANDPKWSTPTKDCTSGPYTAQIIPGTGNKLLMSSPNCEIYYQSPLSLCMAKRKSVSTPVSAQMTSKSCKGEKEIDDQKNCKKRRALDFLSRLPLPPPVSPICTFVSPAAQKAFQPPRSCGTKYETPIKKKELNSPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSESTRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI

Source isoform notes & selection

Isoform sequence differences 0

No annotation is recorded in this UniProt entry.

Sequence conflicts & cautions 5

Scroll across the table for evidence and actions.

5 recorded rows

FeaturePositionDescriptionEvidenceInspect
Sequence conflict758in Ref. 1; CAA64484
S → N
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict1761–1762in Ref. 1; CAA64484
GY → RI
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict1767in Ref. 1; CAA64484
K → N
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict2536in Ref. 4; CAA98995
S → P
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict3216in Ref. 4; CAA97728
L → LVS
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure

Recorded secondary structure 14

Scroll across the table for evidence and actions.

14 recorded rows

FeaturePositionDescriptionEvidenceInspect
Helix31–35Helix
Evidence & references
  • ECO:0007829 PDB:3EU7
No verified residues in this structure
Beta strand203–206Beta strand
Evidence & references
  • ECO:0007829 PDB:6GY2
No verified residues in this structure
Beta strand1219–1221Beta strand
Evidence & references
  • ECO:0007829 PDB:8C3N
No verified residues in this structure
Beta strand1228–1230Beta strand
Evidence & references
  • ECO:0007829 PDB:6HQU
No verified residues in this structure
Helix1231–1242Helix
Evidence & references
  • ECO:0007829 PDB:8C3N
No verified residues in this structure
Beta strand1257–1259Beta strand
Evidence & references
  • ECO:0007829 PDB:8BR9
No verified residues in this structure
Helix1536–1541Helix
Evidence & references
  • ECO:0007829 PDB:1N0W
No verified residues in this structure
Turn1542–1546Turn
Evidence & references
  • ECO:0007829 PDB:1N0W
No verified residues in this structure
Beta strand2058–2060Beta strand
Evidence & references
  • ECO:0007829 PDB:8C3J
No verified residues in this structure
Beta strand2300–2302Beta strand
Evidence & references
  • ECO:0007829 PDB:7LDG
No verified residues in this structure
Helix2311–2314Helix
Evidence & references
  • ECO:0007829 PDB:7LDG
No verified residues in this structure
Beta strand2315–2317Beta strand
Evidence & references
  • ECO:0007829 PDB:7LDG
No verified residues in this structure
Turn3292–3294Turn
Evidence & references
  • ECO:0007829 PDB:8PBC
No verified residues in this structure
Helix3297–3301Helix
Evidence & references
  • ECO:0007829 PDB:8PBC
No verified residues in this structure
12

Homologs

OMA orthologs

Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.

Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.

13

Sources & References

Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.

Source dates & provenance

Recorded 2026-11-10. Source dates and identifiers are retained below.

Publications in this UniProt entry

1 · Identification of the breast cancer susceptibility gene BRCA2.

1995 · Nature

PubMed 8524414 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT ALA-2466

Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G., Barfoot R., Hamoudi R., Patel S., Rice C., Biggs P., Hashim Y., Smith A., Connor F., Arason A., Gudmundsson J., Ficenec D., Kelsell D., Ford D., Tonin P., Bishop D.T., Spurr N.K., Ponder B.A.J., Eeles R., Peto J., Devilee P., Cornelisse C., Lynch H., Narod S., Lenoir G., Egilsson V., Barkadottir R.B., Easton D.F., Bentley D.R., Futreal P.A., Ashworth A., Stratton M.R.

2 · The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.

1996 · Nat. Genet.

PubMed 8589730 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA]; TISSUE SPECIFICITY; VARIANTS HIS-372 AND PHE-599; VARIANT ALA-2466

Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D., Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T., Dumont M., Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P., Kehrer R., Leblanc J.-F., Mitchell J.T., McArthur-Morrison J., Nguyen K., Peng Y., Samson C., Schroeder M., Snyder S.C., Steele L., Stringfellow M., Stroup C., Swedlund B., Swensen J., Teng D., Thomas A., Tran T., Tran T., Tranchant M., Weaver-Feldhaus J., Wong A.K.C., Shizuya H., Eyfjord J.E., Cannon-Albright L., Labrie F., Skolnick M.H., Weber B., Kamb A., Goldar D.E.

· Reference

OCT-2003 ·

Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS HIS-289; GLN-322; HIS-372; VAL-784; SER-929; PHE-976; ILE-987; ASP-991; ASN-1561; LYS-1880; MET-1915; PHE-2138; ARG-2162; ARG-2440; ALA-2466; THR-2490; PRO-2835; ALA-2856; PHE-2944; THR-2951; ILE-3244 AND VAL-3412

4 · The DNA sequence and analysis of human chromosome 13.

2004 · Nature

PubMed 15057823 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT ALA-2466

Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L., Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.

All source publications (98)
5 · Linkage to BRCA2 region in hereditary male breast cancer.

1995 · Lancet

PubMed 7658781 ↗
Scope & authors

INVOLVEMENT IN BROVCA2

Thorlacius S., Tryggvadottir L., Olafsdottir G.H., Jonasson J.G., Ogmundsdottir H.M., Tulinius H., Eyfjord J.E.

6 · Study of a single BRCA2 mutation with high carrier frequency in a small population.

1997 · Am. J. Hum. Genet.

PubMed 9150155 ↗
Scope & authors

INVOLVEMENT IN BROVCA2

Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J.G., Tryggvadottir L., Tulinius H., Eyfjoerd J.E.

7 · Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients.

1997 · Nat. Genet.

PubMed 9140390 ↗
Scope & authors

INVOLVEMENT IN PNCA2

Ozcelik H., Schmocker B., Di Nicola N., Shi X.H., Langer B., Moore M., Taylor B.R., Narod S.A., Darlington G., Andrulis I.L., Gallinger S., Redston M.

8 · Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.

1999 · Lancet

PubMed 10584720 ↗
Scope & authors

INVOLVEMENT IN BROVCA2

Jernstroem H., Lerman C., Ghadirian P., Lynch H.T., Weber B., Garber J., Daly M., Olopade O.I., Foulkes W.D., Warner E., Brunet J.S., Narod S.A.

9 · Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals.

1999 · Mol. Cell. Biol.

PubMed 10373512 ↗
Scope & authors

INTERACTION WITH SEM1

Marston N.J., Richards W.J., Hughes D., Bertwistle D., Marshall C.J., Ashworth A.

10 · De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.

2001 · J. Med. Genet.

PubMed 11158174 ↗
Scope & authors

INVOLVEMENT IN BROVCA2

van der Luijt R.B., van Zon P.H., Jansen R.P., van der Sijs-Bos C.J., Warlam-Rodenhuis C.C., Ausems M.G.

11 · Role of BRCA2 in control of the RAD51 recombination and DNA repair protein.

2001 · Mol. Cell

PubMed 11239456 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51

Davies A.A., Masson J.Y., McIlwraith M.J., Stasiak A.Z., Stasiak A., Venkitaraman A.R., West S.C.

12 · Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways.

2004 · Hum. Mol. Genet.

PubMed 15115758 ↗
Scope & authors

FUNCTION; INTERACTION WITH FANCD2

Hussain S., Wilson J.B., Medhurst A.L., Hejna J., Witt E., Ananth S., Davies A., Masson J.-Y., Moses R., West S.C., de Winter J.P., Ashworth A., Jones N.J., Mathew C.G.

13 · Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin.

2004 · Mol. Cell. Biol.

PubMed 15199141 ↗
Scope & authors

FUNCTION; PHOSPHORYLATION; INTERACTION WITH FANCD2

Wang X.Z., Andreassen P.R., D'Andrea A.D.

14 · BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage.

2004 · Mol. Cell. Biol.

PubMed 15314155 ↗
Scope & authors

UBIQUITINATION; DEUBIQUITINATION; INTERACTION WITH USP11

Schoenfeld A.R., Apgar S., Dolios G., Wang R., Aaronson S.A.

15 · Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour.

2005 · J. Med. Genet.

PubMed 15689453 ↗
Scope & authors

INVOLVEMENT IN GLM3

Reid S., Renwick A., Seal S., Baskcomb L., Barfoot R., Jayatilake H., Pritchard-Jones K., Stratton M.R., Ridolfi-Luethy A., Rahman N.

16 · FANCD2 functions independently of BRCA2 and RAD51 associated homologous recombination in response to DNA damage.

2005 · J. Biol. Chem.

PubMed 15671039 ↗
Scope & authors

FUNCTION

Ohashi A., Zdzienicka M.Z., Chen J., Couch F.J.

17 · CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.

2005 · Nature

PubMed 15800615 ↗
Scope & authors

PHOSPHORYLATION AT SER-3291 BY CDK2; INTERACTION WITH RAD51; MUTAGENESIS OF SER-3291

Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., West S.C.

18 · BRCA2 BRC motifs bind RAD51-DNA filaments.

2005 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 15937124 ↗
Scope & authors

FUNCTION; INTERACTION WITH RAD51; DOMAIN

Galkin V.E., Esashi F., Yu X., Yang S., West S.C., Egelman E.H.

19 · WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation.

2005 · Neoplasia

PubMed 15967112 ↗
Scope & authors

INTERACTION WITH WDR16

Silva F.P., Hamamoto R., Nakamura Y., Furukawa Y.

20 · Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

2006 · Mol. Cell

PubMed 16793542 ↗
Scope & authors

INTERACTION WITH PALB2; CHARACTERIZATION OF VARIANTS BC ARG-25; CYS-31 AND ARG-31

Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X., Jasin M., Couch F.J., Livingston D.M.

21 · DSS1 is required for the stability of BRCA2.

2006 · Oncogene

PubMed 16205630 ↗
Scope & authors

INTERACTION WITH SEM1

Li J., Zou C., Bai Y., Wazer D.E., Band V., Gao Q.

22 · Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2.

2007 · Nat. Struct. Mol. Biol.

PubMed 17515904 ↗
Scope & authors

FUNCTION; INTERACTION WITH RAD51; DOMAIN

Esashi F., Galkin V.E., Yu X., Egelman E.H., West S.C.

23 · Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats.

2007 · Nat. Struct. Mol. Biol.

PubMed 17515903 ↗
Scope & authors

FUNCTION; INTERACTION WITH RAD51; DOMAIN; PHOSPHORYLATION AT SER-3291

Davies O.R., Pellegrini L.

24 · ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

2007 · Science

PubMed 17525332 ↗
Scope & authors

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-755; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.

25 · FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.

2008 · Oncogene

PubMed 18212739 ↗
Scope & authors

INTERACTION WITH FANCD2; FANCG AND XRCC3

Wilson J.B., Yamamoto K., Marriott A.S., Hussain S., Sung P., Hoatlin M.E., Mathew C.G., Takata M., Thompson L.H., Kupfer G.M., Jones N.J.

26 · The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage.

2008 · Oncogene

PubMed 18317453 ↗
Scope & authors

FUNCTION IN RAD51-DEPENDENT DNA REPAIR; PHOSPHORYLATION AT THR-3387 BY CHEK1 AND CHEK2; MUTAGENESIS OF THR-3387; INTERACTION WITH RAD51

Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E., Stambrook P.J.

27 · The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51.

2009 · Cell

PubMed 19303847 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51; DOMAIN

Carreira A., Hilario J., Amitani I., Baskin R.J., Shivji M.K., Venkitaraman A.R., Kowalczykowski S.C.

28 · PALB2 is an integral component of the BRCA complex required for homologous recombination repair.

2009 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 19369211 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY; IDENTIFICATION IN A BRCA COMPLEX WITH BRCA1 AND PALB2

Sy S.M., Huen M.S., Chen J.

29 · Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA.

2010 · Nat. Struct. Mol. Biol.

PubMed 20729859 ↗
Scope & authors

FUNCTION; INTERACTION WITH RAD51

Liu J., Doty T., Gibson B., Heyer W.D.

30 · The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.

2010 · Nat. Struct. Mol. Biol.

PubMed 20729858 ↗
Scope & authors

FUNCTION; SUBUNIT

Thorslund T., McIlwraith M.J., Compton S.A., Lekomtsev S., Petronczki M., Griffith J.D., West S.C.

31 · BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.

2010 · Nat. Struct. Mol. Biol.

PubMed 21076401 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51

Badie S., Escandell J.M., Bouwman P., Carlos A.R., Thanasoula M., Gallardo M.M., Suram A., Jaco I., Benitez J., Herbig U., Blasco M.A., Jonkers J., Tarsounas M.

32 · Purified human BRCA2 stimulates RAD51-mediated recombination.

2010 · Nature

PubMed 20729832 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY; FUNCTION; INTERACTION WITH RAD51 AND DMC1

Jensen R.B., Carreira A., Kowalczykowski S.C.

33 · BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2.

2011 · Cancer Res.

PubMed 21084279 ↗
Scope & authors

FUNCTION; INTERACTION WITH ROCK2 AND NPM1

Wang H.F., Takenaka K., Nakanishi A., Miki Y.

34 · Homologous recombination proteins are associated with centrosomes and are required for mitotic stability.

2011 · Exp. Cell Res.

PubMed 21276791 ↗
Scope & authors

SUBCELLULAR LOCATION

Cappelli E., Townsend S., Griffin C., Thacker J.

35 · Toward a comprehensive characterization of a human cancer cell phosphoproteome.

2013 · J. Proteome Res.

PubMed 23186163 ↗
Scope & authors

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-445; SER-492; SER-1970; THR-2035; SER-2095 AND SER-3319; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.

36 · A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.

2013 · Nat. Struct. Mol. Biol.

PubMed 24013206 ↗
Scope & authors

INTERACTION WITH SEM1; CHARACTERIZATION OF VARIANT BC HIS-2723; MUTAGENESIS OF TRP-2725; NUCLEAR EXPORT SIGNAL; SUBCELLULAR LOCATION

Jeyasekharan A.D., Liu Y., Hattori H., Pisupati V., Jonsdottir A.B., Rajendra E., Lee M., Sundaramoorthy E., Schlachter S., Kaminski C.F., Ofir-Rosenfeld Y., Sato K., Savill J., Ayoub N., Venkitaraman A.R.

37 · Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.

2014 · Oncogene

PubMed 24141787 ↗
Scope & authors

INTERACTION WITH PALB2; IDENTIFICATION IN A PALB2-CONTAINING HR COMPLEX

Park J.Y., Singh T.R., Nassar N., Zhang F., Freund M., Hanenberg H., Meetei A.R., Andreassen P.R.

38 · Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in recombination-associated DNA synthesis at blocked replication forks.

2014 · Cell Rep.

PubMed 24485656 ↗
Scope & authors

FUNCTION; INTERACTION WITH POLH

Buisson R., Niraj J., Pauty J., Maity R., Zhao W., Coulombe Y., Sung P., Masson J.Y.

39 · BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2.

2014 · Nature

PubMed 24896180 ↗
Scope & authors

FUNCTION IN R-LOOP PROCESSING; INTERACTION WITH SEM1 AND PCID2

Bhatia V., Barroso S.I., Garcia-Rubio M.L., Tumini E., Herrera-Moyano E., Aguilera A.

40 · A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.

2016 · Genes Dev.

PubMed 27941124 ↗
Scope & authors

FUNCTION; INTERACTION WITH RAD51

Luo K., Li L., Li Y., Wu C., Yin Y., Chen Y., Deng M., Nowsheen S., Yuan J., Lou Z.

41 · Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability.

2016 · Mol. Cell

PubMed 26833090 ↗
Scope & authors

IDENTIFICATION IN THE HR COMPLEX; INTERACTION WITH ERCC5 AND PALB2; SUBCELLULAR LOCATION

Trego K.S., Groesser T., Davalos A.R., Parplys A.C., Zhao W., Nelson M.R., Hlaing A., Shih B., Rydberg B., Pluth J.M., Tsai M.S., Hoeijmakers J.H.J., Sung P., Wiese C., Campisi J., Cooper P.K.

42 · BRCA2 regulates DMC1-mediated recombination through the BRC repeats.

2016 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 26976601 ↗
Scope & authors

FUNCTION; INTERACTION WITH DMC1

Martinez J.S., von Nicolai C., Kim T., Ehlen A., Mazin A.V., Kowalczykowski S.C., Carreira A.

43 · Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.

2017 · Oncogene

PubMed 28319063 ↗
Scope & authors

INTERACTION WITH PALB2

Foo T.K., Tischkowitz M., Simhadri S., Boshari T., Zayed N., Burke K.A., Berman S.H., Blecua P., Riaz N., Huo Y., Ding Y.C., Neuhausen S.L., Weigelt B., Reis-Filho J.S., Foulkes W.D., Xia B.

44 · HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis.

2019 · Cell Rep.

PubMed 31242413 ↗
Scope & authors

INTERACTION WITH HSF2BP

Brandsma I., Sato K., van Rossum-Fikkert S.E., van Vliet N., Sleddens E., Reuter M., Odijk H., van den Tempel N., Dekkers D.H.W., Bezstarosti K., Demmers J.A.A., Maas A., Lebbink J., Wyman C., Essers J., van Gent D.C., Baarends W.M., Knipscheer P., Kanaar R., Zelensky A.N.

45 · C1orf112 teams up with FIGNL1 to facilitate RAD51 filament disassembly and DNA interstrand cross-link repair.

2023 · Cell Rep.

PubMed 37515771 ↗
Scope & authors

FUNCTION

Zhou Z., Yang H., Liang X., Zhou T., Zhang T., Yang Y., Wang J., Wang W.

46 · Visualization of direct and diffusion-assisted RAD51 nucleation by full-length human BRCA2 protein.

2023 · Mol. Cell

PubMed 37499663 ↗
Scope & authors

FUNCTION; SUBCELLULAR LOCATION; INTERACTION WITH RAD51

Belan O., Greenhough L., Kuhlen L., Anand R., Kaczmarczyk A., Gruszka D.T., Yardimci H., Zhang X., Rueda D.S., West S.C., Boulton S.J.

47 · Insights into DNA recombination from the structure of a RAD51-BRCA2 complex.

2002 · Nature

PubMed 12442171 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH RAD51; FUNCTION; INTERACTION WITH RAD51

Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., Venkitaraman A.R.

48 · Structural basis for recruitment of BRCA2 by PALB2.

2009 · EMBO Rep.

PubMed 19609323 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH PALB2

Oliver A.W., Swift S., Lord C.J., Ashworth A., Pearl L.H.

49 · BRCA2 stabilises RAD51 and DMC1 nucleoprotein filaments through a conserved interaction mode.

2024 · Nat. Commun.

PubMed 39333100 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH DMC1; INTERACTION WITH DMC1; MUTAGENESIS OF PHE-2406; PRO-2408 AND PRO-2409

Dunce J.M., Davies O.R.

50 · DMC1 and RAD51 bind FxxA and FxPP motifs of BRCA2 via two separate interfaces.

2024 · Nucleic Acids Res.

PubMed 38828772 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY IN COMPLEX WITH DMC1; INTERACTION WITH DMC1; MUTAGENESIS OF ARG-2401; LYS-2404; 2406-PHE--PRO-2409; 2411-LYS--LYS-2413; LYS-2411 AND LYS-2413

Miron S., Legrand P., Dupaigne P., van Rossum-Fikkert S.E., Ristic D., Majeed A., Kanaar R., Zinn-Justin S., Zelensky A.N.

51 · Mutations of the BRCA2 gene in ovarian carcinomas.

1996 · Cancer Res.

PubMed 8665505 ↗
Scope & authors

VARIANT OVARIAN CANCER HIS-2787; VARIANTS HIS-372; MET-1915 AND ALA-2466

Takahashi H., Chiu H.-C., Bandera C.A., Behbakht K., Liu P.C., Couch F.J., Weber B.L., LiVolsi V.A., Furusato M., Rebane B.A., Cardonick A., Benjamin I., Morgan M.A., King S.A., Mikuta J.J., Rubin S.C., Boyd J.

52 · BRCA2 germline mutations in male breast cancer cases and breast cancer families.

1996 · Nat. Genet.

PubMed 8673091 ↗
Scope & authors

VARIANTS HIS-372; ASP-991; SER-1147; MET-1915 AND CYS-2034

Couch F.J., Farid L.M., Deshano M.L., Tavtigian S.V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S., Shattuck-Eidens D., Godwin A.K., Daly M., Radford D.M., Sedlacek S., Rommens J., Simard J., Garber J., Merajver S., Weber B.L.

53 · BRCA2 mutations in primary breast and ovarian cancers.

1996 · Nat. Genet.

PubMed 8640235 ↗
Scope & authors

VARIANT GLU-3095

Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G., Patel S., Hamoudi R., Larsson C., Wiseman R.W., Berchuck A., Iglehart J.D., Marks J.R., Ashworth A., Stratton M.R., Futreal P.A.

54 · Low incidence of BRCA2 mutations in breast carcinoma and other cancers.

1996 · Nat. Genet.

PubMed 8640236 ↗
Scope & authors

VARIANTS

Teng D.H.-F., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S., Davis T., Ha P.C., Kehrer R., Jammulapati S., Chen Q., Offit K., Skolnick M.H., Tavtigian S.V., Jhanwar S., Swedlund B., Wong A.K.C., Kamb A.

55 · Mutation analysis in the BRCA2 gene in primary breast cancers.

1996 · Nat. Genet.

PubMed 8640237 ↗
Scope & authors

VARIANT BC ASN-2415

Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y.

56 · A low proportion of BRCA2 mutations in Finnish breast cancer families.

1997 · Am. J. Hum. Genet.

PubMed 9150152 ↗
Scope & authors

VARIANT BC ASP-2089; VARIANT VAL-3412

Vehmanen P., Friedman L.S., Eerola H., Sarantaus L., Pyrhoenen S., Ponder B.A.J., Muhonen T., Nevanlinna H.

57 · High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.

1998 · Hum. Genet.

PubMed 9654203 ↗
Scope & authors

VARIANT BC/PANCREAS CANCER TRP-554

Ganguly T., Dhulipala R., Godmilow L., Ganguly A.

58 · High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.

1998 · J. Hum. Genet.

PubMed 9609997 ↗
Scope & authors

VARIANTS BC LEU-32; ARG-53; LEU-81; ARG-201; ALA-211; SER-222 AND THR-3118

Katagiri T., Kasumi F., Yoshimoto M., Nomizu T., Asaishi K., Abe R., Tsuchiya A., Sugano M., Takai S., Yoneda M., Fukutomi T., Nanba K., Makita M., Okazaki H., Hirata K., Okazaki M., Furutsuma Y., Morishita Y., Iino Y., Karino T., Ayabe H., Hara S., Kajiwara T., Houga S., Shimizu T., Toda M., Yamazaki Y., Uchida T., Kunitomo K., Sonoo H., Kurebayashi J., Shimotsuma K., Nakamura Y., Miki Y.

59 · The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.

1999 · Am. J. Hum. Genet.

PubMed 10486320 ↗
Scope & authors

VARIANTS OVARIAN CANCER PRO-75; HIS-2502 AND HIS-3098

Gayther S.A., Russell P., Harrington P., Antoniou A.C., Easton D.F., Ponder B.A.J.

60 · Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan.

1999 · Hum. Genet.

PubMed 10323242 ↗
Scope & authors

VARIANTS HIS-289; HIS-372; ASP-991 AND VAL-3412

Li S.S.-L., Tseng H.-M., Yang T.-P., Liu C.-H., Teng S.-J., Huang H.-W., Chen L.-M., Kao H.-W., Chen J.H., Tseng J.-N., Chen A., Hou M.-F., Huang T.-J., Chang H.-T., Mok K.-T., Tsai J.-H.

61 · Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations.

1999 · Hum. Mol. Genet.

PubMed 9971877 ↗
Scope & authors

VARIANTS BC GLU-327 AND ASN-935; VARIANTS

Wagner T.M.U., Hirtenlehner K., Shen P., Moeslinger R., Muhr D., Fleischmann E., Concin H., Doeller W., Haid A., Lang A.H., Mayer P., Petru E., Ropp E., Langbauer G., Kubista E., Scheiner O., Underhill P., Mountain J., Stierer M., Zielinski C., Oefner P.

62 · Germline brca2 sequence variants in patients with ocular melanoma.

1999 · Int. J. Cancer

PubMed 10399947 ↗
Scope & authors

VARIANT BC ARG-326; VARIANT ILE-2728

Sinilnikova O.M., Egan K.M., Quinn J.L., Boutrand L., Lenoir G.M., Stoppa-Lyonnet D., Desjardins L., Levy C., Goldgar D., Gragoudas E.S.

63 · A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.

2000 · Nat. Genet.

PubMed 11062481 ↗
Scope & authors

VARIANT HIS-372

Healey C.S., Dunning A.M., Teare M.D., Chase D., Parker L., Burn J., Chang-Claude J., Mannermaa A., Kataja V., Huntsman D.G., Pharoah P.D.P., Luben R.N., Easton D.F., Ponder B.A.J.

64 · BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease.

2000 · J. Med. Genet.

PubMed 10978364 ↗
Scope & authors

VARIANTS BC MET-729; ILE-2515 AND ILE-2728; VARIANTS HIS-289; HIS-372; ASP-991; MET-1915 AND VAL-3412

Plaschke J., Commer T., Jacobi C., Schackert H.K., Chang-Claude J.

65 · BRCA2 germline mutations in male breast cancer patients in the Polish population.

2001 · Hum. Mutat.

PubMed 11139248 ↗
Scope & authors

VARIANTS BC ASN-1179; ILE-3124 AND GLU-3196; VARIANT TYR-1420

Kwiatkowska E., Teresiak M., Lamperska K.M., Karczewska A., Breborowicz D., Stawicka M., Godlewski D., Krzyzosiak W.J., Mackiewicz A.

66 · An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD).

2001 · Hum. Mutat.

PubMed 11241844 ↗
Scope & authors

VARIANTS BC THR-505; TYR-1730; HIS-2135 AND CYS-2222; VARIANT LYS-1880

Edwards S.M., Kote-Jarai Z., Hamoudi R., Eeles R.A.

67 · Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.

2001 · Int. J. Cancer

PubMed 11149425 ↗
Scope & authors

VARIANTS HIS-289 AND VAL-784; VARIANT BC GLU-3076

Ikeda N., Miyoshi Y., Yoneda K., Shiba E., Sekihara Y., Kinoshita M., Noguchi S.

68 · BRCA2 T2722R is a deleterious allele that causes exon skipping.

2002 · Am. J. Hum. Genet.

PubMed 12145750 ↗
Scope & authors

VARIANT BC ARG-2722

Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.

· Reference

2002 · Am. J. Hum. Genet.

Scope & authors

ERRATUM OF PUBMED:12145750

Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.

70 · BRCA2 gene mutations in families with aggregations of breast and stomach cancers.

2002 · Br. J. Cancer

PubMed 12373604 ↗
Scope & authors

VARIANTS BC CYS-2072; CYS-2094 AND ASN-2128

Jakubowska A., Nej K., Huzarski T., Scott R.J., Lubinski J.

71 · Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

2002 · Cancer Res.

PubMed 12097290 ↗
Scope & authors

VARIANT THR-192

Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., Hruban R.H., Kern S.E.

72 · Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma.

2002 · Clin. Cancer Res.

PubMed 11948123 ↗
Scope & authors

VARIANTS HIS-118; SER-315; ILE-1988; CYS-2842 AND SER-3300

Hu N., Li G., Li W.-J., Wang C., Goldstein A.M., Tang Z.-Z., Roth M.J., Dawsey S.M., Huang J., Wang Q.-H., Ding T., Giffen C., Taylor P.R., Emmert-Buck M.R.

73 · Characterization of common BRCA1 and BRCA2 variants.

2002 · Genet. Test.

PubMed 12215251 ↗
Scope & authors

VARIANTS ALA-598; TYR-1420; CYS-2034; ILE-2728 AND THR-2951

Deffenbaugh A.M., Frank T.S., Hoffman M., Cannon-Albright L., Neuhausen S.L.

74 · BRCA1 and BRCA2 in Indian breast cancer patients.

2002 · Hum. Mutat.

PubMed 12442273 ↗
Scope & authors

VARIANTS ASP-1593 AND SER-2706

Saxena S., Szabo C.I., Chopin S., Barjhoux L., Sinilnikova O., Lenoir G., Goldgar D.E., Bhatanager D.

75 · BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.

2002 · Hum. Mutat.

PubMed 12442274 ↗
Scope & authors

VARIANT BC ASN-2729; VARIANT VAL-3412

Zhi X., Szabo C., Chopin S., Suter N., Wang Q.-S., Ostrander E.A., Sinilnikova O.M., Lenoir G.M., Goldgar D., Shi Y.-R.

76 · BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico.

2002 · Hum. Mutat.

PubMed 12442275 ↗
Scope & authors

VARIANTS BC CYS-42; ARG-613; LEU-2118; LEU-2293 AND ARG-2793; VARIANT ILE-3374

Ruiz-Flores P., Sinilnikova O.M., Badzioch M., Calderon-Garciduenas A.L., Chopin S., Fabrice O., Gonzalez-Guerrero J.F., Szabo C., Lenoir G., Goldgar D.E., Barrera-Saldana H.A.

77 · Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer.

2002 · Int. J. Cancer

PubMed 11948477 ↗
Scope & authors

VARIANTS BC TYR-1580 AND MET-1915

Kwiatkowska E., Teresiak M., Breborowicz D., Mackiewicz A.

78 · Biallelic inactivation of BRCA2 in Fanconi anemia.

2002 · Science

PubMed 12065746 ↗
Scope & authors

INVOLVEMENT IN FANCD1

Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., de Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., D'Andrea A.D.

79 · BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer.

2003 · Hum. Mutat.

PubMed 12552570 ↗
Scope & authors

VARIANTS HIS-289; HIS-372; GLY-462; ASP-991; SER-1279; TYR-1420; ASP-1771 AND ALA-2466

Hadjisavvas A., Charalambous E., Adamou A., Christodoulou C.G., Kyriacou K.

80 · Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.

2003 · Hum. Mutat.

PubMed 12938098 ↗
Scope & authors

VARIANTS BC ILE-431; LYS-1036; ARG-1106 AND VAL-1524

Meyer P., Voigtlaender T., Bartram C.R., Klaes R.

81 · Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1and BRCA2genes in familial breast cancer.

2003 · J. Hum. Genet.

PubMed 12624724 ↗
Scope & authors

VARIANTS PRO-582; PHE-1522 AND VAL-2044

Sakayori M., Kawahara M., Shiraishi K., Nomizu T., Shimada A., Kudo T., Abe R., Ohuchi N., Takenoshita S., Kanamaru R., Ishioka C.

82 · BRCA2 germline mutations in familial pancreatic carcinoma.

2003 · J. Natl. Cancer Inst.

PubMed 12569143 ↗
Scope & authors

VARIANT CYS-2034; VARIANT BC GLU-3076

Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D., Gruetzmann R., Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P., Bartsch D.K.

83 · Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.

2004 · Blood

PubMed 14670928 ↗
Scope & authors

VARIANT FANCD1 PRO-2510

Hirsch B., Shimamura A., Moreau L., Baldinger S., Hag-alshiekh M., Bostrom B., Sencer S., D'Andrea A.D.

84 · BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.

2004 · Br. J. Cancer

PubMed 15026808 ↗
Scope & authors

VARIANTS BC SER-60; ARG-405; HIS-448; GLY-462; GLY-2275; ARG-2353; LYS-2488; HIS-2723; ASN-2950; ILE-3013 AND HIS-3098; VARIANTS ASP-991; ALA-2856 AND VAL-3412

Claes K., Poppe B., Coene I., De Paepe A., Messiaen L.

85 · Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.

2004 · Cancer Genet. Cytogenet.

PubMed 15172753 ↗
Scope & authors

VARIANTS BC ILE-64; GLY-462; ASN-1690; ASP-1771; MET-1887; MET-1915 AND GLU-2456; VARIANTS HIS-289; HIS-372; ASP-991; SER-1279; TYR-1420; CYS-2108 AND ALA-2466

Hadjisavvas A., Charalambous E., Adamou A., Neuhausen S.L., Christodoulou C.G., Kyriacou K.

86 · One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

2004 · Eur. J. Cancer

PubMed 14746861 ↗
Scope & authors

VARIANT OVARIAN CANCER CYS-42; VARIANTS SER-3063 AND VAL-3412

Malander S., Ridderheim M., Masbaeck A., Loman N., Kristoffersson U., Olsson H., Nilbert M., Borg A.

87 · Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.

2004 · Hum. Mutat.

PubMed 14722926 ↗
Scope & authors

VARIANTS BC ILE-1679; ALA-1804; LYS-1901 AND LEU-2096

Valarmathi M.T., Sawhney M., Deo S.S.V., Shukla N.K., Das S.N.

88 · RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.

2004 · Hum. Mutat.

PubMed 15300854 ↗
Scope & authors

VARIANT ALA-225; CHARACTERIZATION OF VARIANT ALA-225

Sharp A., Pichert G., Lucassen A., Eccles D.

89 · BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.

2004 · Hum. Mutat.

PubMed 15365993 ↗
Scope & authors

VARIANTS BC THR-1445; VAL-1929 AND ALA-2031; VARIANTS HIS-289; HIS-372; VAL-784; ASP-991 AND VAL-3412

Seo J.H., Cho D.-Y., Ahn S.-H., Yoon K.-S., Kang C.-S., Cho H.M., Lee H.S., Choe J.J., Choi C.W., Kim B.S., Shin S.W., Kim Y.H., Kim J.S., Son G.-S., Lee J.-B., Koo B.H.

90 · Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases.

2005 · J. Med. Genet.

PubMed 15635067 ↗
Scope & authors

VARIANTS LEU-1172; TYR-1420; PHE-2944; ASN-2950 AND ILE-3013

Kim S.-W., Lee C.S., Fey J.V., Borgen P.I., Boyd J.

91 · A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

2007 · Am. J. Hum. Genet.

PubMed 17924331 ↗
Scope & authors

VARIANTS BC CYS-2502; PHE-2627; PRO-2653; LYS-2659; VAL-2663; ARG-2722; GLY-2723; ASP-2748 AND GLU-3095; VARIANTS FANCD1 HIS-2336 AND CYS-2626

Easton D.F., Deffenbaugh A.M., Pruss D., Frye C., Wenstrup R.J., Allen-Brady K., Tavtigian S.V., Monteiro A.N.A., Iversen E.S., Couch F.J., Goldgar D.E.

92 · Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.

2007 · J. Med. Genet.

PubMed 16825431 ↗
Scope & authors

VARIANTS FANCD1 HIS-2336 AND CYS-2626

Alter B.P., Rosenberg P.S., Brody L.C.

93 · Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.

2010 · Hum. Mutat.

PubMed 20513136 ↗
Scope & authors

CHARACTERIZATION OF VARIANTS VAL-2663; GLY-2723 AND TRP-3052

Walker L.C., Whiley P.J., Couch F.J., Farrugia D.J., Healey S., Eccles D.M., Lin F., Butler S.A., Goff S.A., Thompson B.A., Lakhani S.R., Da Silva L.M., Tavtigian S.V., Goldgar D.E., Brown M.A., Spurdle A.B.

94 · A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.

2011 · Blood

PubMed 21719596 ↗
Scope & authors

CHARACTERIZATION OF VARIANTS FANCD1 HIS-2336; PRO-2510 AND CYS-2626; CHARACTERIZATION OF VARIANTS THR-2490 AND ASN-2729; FUNCTION; INTERACTION WITH SEM1

Biswas K., Das R., Alter B.P., Kuznetsov S.G., Stauffer S., North S.L., Burkett S., Brody L.C., Meyer S., Byrd R.A., Sharan S.K.

95 · A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.

2013 · Cancer Res.

PubMed 23108138 ↗
Scope & authors

CHARACTERIZATION OF VARIANTS BC PHE-2627; PRO-2653; ARG-2722; GLY-2723; HIS-2723; ASN-2729; HIS-2787; PRO-2792; ARG-2793; ALA-2856; THR-2951; ILE-3013; TRP-3052; GLU-3076; GLU-3095; HIS-3098 AND ILE-3124; CHARACTERIZATION OF VARIANTS ARG-2440; ALA-2466; CYS-2842 AND SER-3063; CHARACTERIZATION OF VARIANT FANCD1 PRO-2510 AND CYS-2626

Guidugli L., Pankratz V.S., Singh N., Thompson J., Erding C.A., Engel C., Schmutzler R., Domchek S., Nathanson K., Radice P., Singer C., Tonin P.N., Lindor N.M., Goldgar D.E., Couch F.J.

96 · Homozygous missense mutation in the LMAN2L gene segregates with intellectual disability in a large consanguineous Pakistani family.

2016 · J. Med. Genet.

PubMed 26566883 ↗
Scope & authors

VARIANTS LEU-606 AND TYR-1420

Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G., Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.

97 · BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?

2017 · PLoS ONE

PubMed 29161300 ↗
Scope & authors

VARIANT BC ALA-728

Alemar B., Gregorio C., Herzog J., Matzenbacher Bittar C., Brinckmann Oliveira Netto C., Artigalas O., Schwartz I.V.D., Coffa J., Alves Camey S., Weitzel J., Ashton-Prolla P.

98 · Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.

2018 · Lancet Oncol.

PubMed 29753700 ↗
Scope & authors

INVOLVEMENT IN MDB

Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.

Fanconi Anemia Mutation Database ↗

Wikipedia ↗

Atlas of Genetics and Cytogenetics in Oncology and Haematology ↗

Annotation coverage audit

Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.

242 source comments and features accounted for.

View annotation inventory
Source recordTypeSection
FUNCTION:0FUNCTIONfunction
SUBUNIT:0SUBUNITinteractions
INTERACTION:0INTERACTIONinteractions
SUBCELLULAR LOCATION:0SUBCELLULAR LOCATIONlocation
TISSUE SPECIFICITY:0TISSUE SPECIFICITYexpression
DOMAIN:0DOMAINdomains
PTM:0PTMprocessing
PTM:1PTMprocessing
DISEASE:0DISEASEdisease
DISEASE:1DISEASEdisease
DISEASE:2DISEASEdisease
DISEASE:3DISEASEdisease
DISEASE:4DISEASEdisease
DISEASE:5DISEASEdisease
WEB RESOURCE:0WEB RESOURCEsources
WEB RESOURCE:1WEB RESOURCEsources
WEB RESOURCE:2WEB RESOURCEsources
feature-0Chainprocessing
feature-1Repeatdomains
feature-2Repeatdomains
feature-3Repeatdomains
feature-4Repeatdomains
feature-5Repeatdomains
feature-6Repeatdomains
feature-7Repeatdomains
feature-8Repeatdomains
feature-9Regiondomains
feature-10Regiondomains
feature-11Regiondomains
feature-12Regiondomains
feature-13Regiondomains
feature-14Regiondomains
feature-15Regiondomains
feature-16Regiondomains
feature-17Regiondomains
feature-18Regiondomains
feature-19Regiondomains
feature-20Regiondomains
feature-21Regiondomains
feature-22Motifdomains
feature-23Compositional biasdomains
feature-24Modified residueprocessing
feature-25Modified residueprocessing
feature-26Modified residueprocessing
feature-27Modified residueprocessing
feature-28Modified residueprocessing
feature-29Modified residueprocessing
feature-30Modified residueprocessing
feature-31Modified residueprocessing
feature-32Modified residueprocessing
feature-33Modified residueprocessing
feature-34Natural variantdisease
feature-35Natural variantdisease
feature-36Natural variantdisease
feature-37Natural variantdisease
feature-38Natural variantdisease
feature-39Natural variantdisease
feature-40Natural variantdisease
feature-41Natural variantdisease
feature-42Natural variantdisease
feature-43Natural variantdisease
feature-44Natural variantdisease
feature-45Natural variantdisease
feature-46Natural variantdisease
feature-47Natural variantdisease
feature-48Natural variantdisease
feature-49Natural variantdisease
feature-50Natural variantdisease
feature-51Natural variantdisease
feature-52Natural variantdisease
feature-53Natural variantdisease
feature-54Natural variantdisease
feature-55Natural variantdisease
feature-56Natural variantdisease
feature-57Natural variantdisease
feature-58Natural variantdisease
feature-59Natural variantdisease
feature-60Natural variantdisease
feature-61Natural variantdisease
feature-62Natural variantdisease
feature-63Natural variantdisease
feature-64Natural variantdisease
feature-65Natural variantdisease
feature-66Natural variantdisease
feature-67Natural variantdisease
feature-68Natural variantdisease
feature-69Natural variantdisease
feature-70Natural variantdisease
feature-71Natural variantdisease
feature-72Natural variantdisease
feature-73Natural variantdisease
feature-74Natural variantdisease
feature-75Natural variantdisease
feature-76Natural variantdisease
feature-77Natural variantdisease
feature-78Natural variantdisease
feature-79Natural variantdisease
feature-80Natural variantdisease
feature-81Natural variantdisease
feature-82Natural variantdisease
feature-83Natural variantdisease
feature-84Natural variantdisease
feature-85Natural variantdisease
feature-86Natural variantdisease
feature-87Natural variantdisease
feature-88Natural variantdisease
feature-89Natural variantdisease
feature-90Natural variantdisease
feature-91Natural variantdisease
feature-92Natural variantdisease
feature-93Natural variantdisease
feature-94Natural variantdisease
feature-95Natural variantdisease
feature-96Natural variantdisease
feature-97Natural variantdisease
feature-98Natural variantdisease
feature-99Natural variantdisease
feature-100Natural variantdisease
feature-101Natural variantdisease
feature-102Natural variantdisease
feature-103Natural variantdisease
feature-104Natural variantdisease
feature-105Natural variantdisease
feature-106Natural variantdisease
feature-107Natural variantdisease
feature-108Natural variantdisease
feature-109Natural variantdisease
feature-110Natural variantdisease
feature-111Natural variantdisease
feature-112Natural variantdisease
feature-113Natural variantdisease
feature-114Natural variantdisease
feature-115Natural variantdisease
feature-116Natural variantdisease
feature-117Natural variantdisease
feature-118Natural variantdisease
feature-119Natural variantdisease
feature-120Natural variantdisease
feature-121Natural variantdisease
feature-122Natural variantdisease
feature-123Natural variantdisease
feature-124Natural variantdisease
feature-125Natural variantdisease
feature-126Natural variantdisease
feature-127Natural variantdisease
feature-128Natural variantdisease
feature-129Natural variantdisease
feature-130Natural variantdisease
feature-131Natural variantdisease
feature-132Natural variantdisease
feature-133Natural variantdisease
feature-134Natural variantdisease
feature-135Natural variantdisease
feature-136Natural variantdisease
feature-137Natural variantdisease
feature-138Natural variantdisease
feature-139Natural variantdisease
feature-140Natural variantdisease
feature-141Natural variantdisease
feature-142Natural variantdisease
feature-143Natural variantdisease
feature-144Natural variantdisease
feature-145Natural variantdisease
feature-146Natural variantdisease
feature-147Natural variantdisease
feature-148Natural variantdisease
feature-149Natural variantdisease
feature-150Natural variantdisease
feature-151Natural variantdisease
feature-152Natural variantdisease
feature-153Natural variantdisease
feature-154Natural variantdisease
feature-155Natural variantdisease
feature-156Natural variantdisease
feature-157Natural variantdisease
feature-158Natural variantdisease
feature-159Natural variantdisease
feature-160Natural variantdisease
feature-161Natural variantdisease
feature-162Natural variantdisease
feature-163Natural variantdisease
feature-164Natural variantdisease
feature-165Natural variantdisease
feature-166Natural variantdisease
feature-167Natural variantdisease
feature-168Natural variantdisease
feature-169Natural variantdisease
feature-170Natural variantdisease
feature-171Natural variantdisease
feature-172Natural variantdisease
feature-173Natural variantdisease
feature-174Natural variantdisease
feature-175Natural variantdisease
feature-176Natural variantdisease
feature-177Natural variantdisease
feature-178Natural variantdisease
feature-179Natural variantdisease
feature-180Natural variantdisease
feature-181Natural variantdisease
feature-182Natural variantdisease
feature-183Natural variantdisease
feature-184Natural variantdisease
feature-185Natural variantdisease
feature-186Natural variantdisease
feature-187Natural variantdisease
feature-188Natural variantdisease
feature-189Natural variantdisease
feature-190Natural variantdisease
feature-191Natural variantdisease
feature-192Natural variantdisease
feature-193Natural variantdisease
feature-194Mutagenesisdisease
feature-195Mutagenesisdisease
feature-196Mutagenesisdisease
feature-197Mutagenesisdisease
feature-198Mutagenesisdisease
feature-199Mutagenesisdisease
feature-200Mutagenesisdisease
feature-201Mutagenesisdisease
feature-202Mutagenesisdisease
feature-203Mutagenesisdisease
feature-204Mutagenesisdisease
feature-205Mutagenesisdisease
feature-206Sequence conflictsequence
feature-207Sequence conflictsequence
feature-208Sequence conflictsequence
feature-209Sequence conflictsequence
feature-210Sequence conflictsequence
feature-211Helixsequence
feature-212Beta strandsequence
feature-213Beta strandsequence
feature-214Beta strandsequence
feature-215Helixsequence
feature-216Beta strandsequence
feature-217Helixsequence
feature-218Turnsequence
feature-219Beta strandsequence
feature-220Beta strandsequence
feature-221Helixsequence
feature-222Beta strandsequence
feature-223Turnsequence
feature-224Helixsequence